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Persistent infection by oncogenic human papillomavirus (HPV) is the primary cause of cervical 
cancer, a leading cause of cancer deaths in women worldwide. There are no treatments for 
HPV infection, and although prophylactic vaccines are effective and safe, they are HPV type 
specific, provide little therapeutic benefit and developing countries often have limited access 
to these. Therefore, additional measures against HPV infection are urgently needed.  
Preventing HPV entry into host cells is an attractive option for therapeutic intervention. The 
HPV capsid is icosahedral and consists of two proteins, L1 and L2, which participate in entry 
and infection of host cells. During entry, the virus capsid attaches to the cell surface via binding 
to heparan sulphate proteoglycans (HSPGs). Cleavage of L2 by a host protease, furin, is 
necessary for infection and is thought to facilitate a conformational change in the virus capsid. 
Furin cleavage may affect the ability of HPV to bind to sulphated glycoproteins and a HSPG 
substitute, heparin.  
Understanding these proposed structural changes may aid in the development of therapeutics 
targeting virus entry. Here, we directly visualize the conformation changes to HPV16 
pseudovirions (HPV16 PsVs) resulting from cleavage of L2 by exogenous furin using cryo-
electron microscopy (cryo-EM).  
At 5 Å resolution, we observed that furin-cleaved HPV16 PsVs capsids display widespread 
changes in the arrangement of capsomeres relative to uncleaved control virions. This 
structural change is relevant because heparin has previously been observed to bind to the 
HPV16 capsid in the canyon surrounding the capsomere at the five-fold icosahedral symmetry 
axis, but not in other canyons between capsomeres, related by pseudo-symmetry. This 
suggests that differences in the relative orientations of the surrounding capsomeres to each 
other either prevent or allow heparin binding. We observed a narrowing of the putative heparin 
binding site by 0.4 Å after furin cleavage and propose that this change may be responsible for 





1.1 Human papillomavirus and cancer 
Papillomaviruses (PVs) are a group of viruses infecting diverse species such as reptiles, birds 
and humans (1, 2). The human papillomaviruses (HPV) are non-enveloped, double-stranded 
DNA viruses, infecting the mucosal and cutaneous epithelia (2-6). HPV infections a are highly 
prevalent sexually transmitted infection and can be classified as low- or high-risk infections, 
based on their oncogenic potential (7, 8). Infection with HPV types of the beta genus are 
considered low-risk as these subtypes cause benign warts and asymptomatic lesions in the 
skin and mucosal epithelia. Although considered low-risk, HPV types 5 and 8 within this genus 
are correlated with the development of cutaneous squamous cell carcinoma, while persistent 
infections with any or a combination of the twelve high-risk HPV types within the alpha genus 
have been linked to several cancers (5-8). High-risk types HPV16 and HPV18 are present in 
72% of HPV associated cancers, making these two HPV types the most common types 
associated with oncogenesis (5, 9-11). As HPV16 is present in many HPV associated cancers 
and is widely studied, HPV16 is the focus of this investigation.  
HPV linked cancers include oropharyngeal, head, and neck cancer and most notably, cervical 
cancer (5, 12-18). Almost all cervical cancer cases are attributed to high-risk HPV infection 
and cervical cancer is the fourth most diagnosed cancer in women worldwide (15, 19, 20). 
Cervical cancer is a leading cause of cancer deaths in women in 42 countries, the majority of 
which are in sub-Saharan Africa, including South Africa (5, 20). The high incidence and 
mortality of cervical cancer in sub-Saharan Africa may be linked to the human 
immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) epidemic within the 
region coupled with under-resourced vaccination and cervical cancer screening programs (9, 
21-23). Indeed, HPV infection is a necessary but insufficient cause of cervical cancer as 
persistent infection over several years as well as co-factors (such as HIV/AIDS induced 
immunosuppression) is needed for possible cancer development (5, 7, 8, 17, 20).  
Sexually active individuals are likely to become infected with one or more HPV type(s) during 
their lifetime, but most of these infections are asymptomatic and can be cleared by the immune 
system within one to two years (18, 24). However, immune clearance is slower for HPV16 and 
related high-risk types, increasing the risk that infection with these viruses will lead to cancer 
(section 1.4) (11, 24). Other co-factors for cervical cancer include high HPV viral load, long-
term oral contraceptive use, tobacco smoking, multiple births, and chronic inflammation. 
Patient genetic and immunological factors are likewise significant in determining the outcome 
of HPV infection. Co-infection with HIV, Herpes simplex virus 2, or Chlamydia trachomatis 
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infection may also increase the risk of cervical cancer (2, 10, 22, 25-27). As persistent high-
risk HPV infection is a key component of cervical cancer development, preventing HPV 
infection may thwart cervical cancer development. Therefore, cervical cancer is potentially an 
entirely avoidable condition. Highly effective and well-tolerated HPV vaccines are available 
but have some shortcomings, despite substantial efforts by vaccination programs (section 
1.2). Consequently, cervical cancer remains a leading cause of cancer deaths in women 
worldwide (20). This makes the development of additional methods to prevent HPV infection 
of critical importance for cervical cancer prevention. 
 
1.2 Current HPV preventative strategies 
Presently, there are no treatments for HPV infection, but prophylactic vaccines trademarked 
as Cervarix™, Gardasil® and Gardasil-9® exist to prevent infection in unexposed individuals.  
(28-35). All three vaccines prevent infection by the most common oncogenic types HPV16 and 
HPV18. Gardasil®  and Gardasil-9® provide additional protection against the non-oncogenic 
HPV types, HPV6 and HPV11 (9, 31, 32, 35). Gardasil-9® provides added protection against 
the oncogenic HPV types 31, 33, 45, 52 and 58 (34, 36). HPV vaccines function by allowing 
the immune system to create antibodies against the HPV type-specific L1 capsid protein, 
eliminating HPV after exposure (33, 37). This process is effective and precise, generating 
antibodies specific to the HPV types vaccinated against (33). For example, in the UK, HPV16 
and 18 prevalence decreased more than 6% in 16-to-18 year old females and more than 10% 
in 19-to-21 year old females after vaccination with Cervarix™, only six years after widespread 
vaccination schemes were implemented (38). In the United States of America, there was a 
decrease in the incidence of cervical precancerous lesions of more than 21% in women who 
had received at least one dose of an HPV vaccine, only six years after vaccine introduction 
(39). These results illustrate that prophylactic vaccination is an effective strategy to prevent 
HPV infection and associated cervical pre-cancers. Importantly, cancer prevention strategies 
are more cost-effective and less invasive than harsh cervical cancer treatment options (40). 
However, these vaccines are not therapeutic and are ineffective against existing cervical 
lesions in HPV infected women (32). Moreover, long-term HPV vaccine efficacy is unknown, 
making screening and other cancer prevention strategies still necessary (10, 40).  
There are other notable shortcomings of the currently available HPV vaccines, most notably 
limited HPV type cross-protection. As the vaccine target protein (the major capsid protein L1) 
differs across HPV types, immune responses to HPV infection are only effective against the 
specific types vaccinated against, rather than a broad cross-protection across different HPV 
types (32, 33, 36, 41). This is especially problematic for individuals at risk for infection by an 
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oncogenic HPV type not currently covered by available vaccines and immuno-compromised 
individuals such as HIV positive individuals, as they are at increased risk of HPV persistence 
and associated cancers (21). Non-vaccine HPV types like HPV35, HPV45 and HPV54 are 
prevalent in Africa, which also has a high HIV/AIDS burden. In a study of women in Nigeria, 
Ghana and South Africa, 97.1% of HIV positive women were also infected with at least one 
HPV type, or several HPV types concurrently including non-vaccine types. These studies also 
emphasise the importance of cervical cancer prevention in HIV positive individuals (21, 42, 
43). However, vaccine uptake is surprisingly low, even in countries with reasonable healthcare 
infrastructure. For example, only 39.7% of all teen girls in the United States of America have 
completed a vaccination regimen (10). In South Africa, school-based vaccinations have been 
implemented by the National Department of Health since 2014 and have been reasonably 
successful, but coverage across resource-limited populations is still poor (44, 45). 
Limited vaccine uptake may be partly explained by cost and accessibility, as the HPV vaccines 
are relatively expensive and require repeat administration for maximum protection. 
Additionally, HPV vaccines are not thermostable, requiring cold storage before use, which is 
difficult to achieve in low resource settings present in rural areas of the world (10, 32, 33, 36). 
This creates a difficult situation for many individuals, who may not be able to afford HPV 
vaccination or are without access to well-resourced vaccination facilities. Another factor 
affecting vaccine uptake, especially in South Africa is reliable knowledge on HPV, as rural 
South African communities are largely unaware of HPV as a risk factor for cervical cancer. 
Cultural stigmas against vaccinating for sexually transmitted diseases may also affect vaccine 
uptake (36).  
Although the available HPV vaccines are safe and effective for type-specific HPV infections, 
their various shortcomings highlight the need for development of alternative therapies 
targeting HPV infection. Possible therapeutic targets include the entry mechanisms used by 
the virus during infection of host cells. However, changes to the HPV capsid during entry, HPV 
receptor use and details of cell attachment entry are insufficiently understood. Therefore, it is 
the focus of the present investigation, to enhance knowledge of structural changes to the HPV 
capsid during entry, as detailed knowledge of proposed changes in capsid conformation during 
entry may aid in the development of small-molecule inhibitors of HPV infection. 
 
1.3  HPV capsid structure and genome  
The HPV capsid is a robust protein shell which encloses and protects viral DNA (Figure 1.1[A]) 
(46). The capsid is ~55 nm in diameter, non-enveloped and icosahedral, made up of 360 
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copies of the major capsid protein L1 (6, 47, 48). Each L1 protein forms a chain (chains A to 
F; Figure 1.1 [B, C]. Five L1 protein chains make up a single capsomere, known as a 
‘pentamer’, (Figure 1.1 [B]), and 72 pentamers make up the HPV capsid (4, 48, 49). These 
pentamers can be arranged in two ways on the HPV capsid. Pentavalent pentamers are made 
up of five L1 chain A’s and arranged with one pentamer surrounded by five other pentamers, 
on the icosahedral five-fold axes of symmetry. Hexavalent pentamers are made up of five L1 
chains B to F, and one hexavalent pentamer is surrounded by six other pentamers (Figure 1.1 
[B]). The spaces between capsomeres form ‘canyons’ within the HPV capsid (Figure 1.1 [A]) 
















Figure 1.1. Graphic representation of the HPV16 capsid, genome, capsomere arrangement and 
asymmetric unit.  [A] Schematic of the papillomavirus capsid and viral genome with associated 
histones as labelled. [B] Arrangements of capsomeres on the HPV capsid. Capsomeres are indicated 
by pentagons made up of five L1 proteins. Hexavalent capsomeres are indicated in blue, while a 
pentavalent capsomere is shown in orange. Each of the five L1 chain within a capsomere is indicated 
by a triangle and labelled with letters. The pentavalent capsomere is made up of five L1 chains labelled 
chain A, while each hexavalent capsomere is made up of five L1 chains labelled chain B, C, D, E, F. 
The flexible carboxyl terminus arms are indicated by coloured lines linking the capsomeres. The orange 
carboxyl terminal arms originate from the pentavalent capsomere, while the blue carboxyl terminal arms 
originate from the hexavalent capsomere. [C] The L1 only asymmetric unit (PDB ID: 5kep) of the HPV16 
capsid is shown, with each (of six) L1 chains labelled as chains A to F. Chain A forms part of the 
pentavalent capsomere and is indicated in orange, while chains B to F, form a hexavalent capsomere 
are coloured in different shades of blue (1, 50). 
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L1 is ~55 kDa in size and can self-assemble into the full viral capsid, even in the absence of 
the second (minor) HPV capsid protein, L2 (2, 47). The five L1 chains within each pentamer 
form a central β jelly roll (Figure 1.2). The carboxyl terminus (C-terminus) of each L1 protein 
(Figure 1.1 [B], Figure 1.2 [B] and [C]) extends outwards to neighbouring capsomeres, through 
spaces between adjacent capsomeres (4, 50). Each L1 protein also contains flexible surface-
exposed loops (Figure 1.2 [B] and [C]), which are often the site of antibody binding and are 
poorly conserved across papillomavirus species (51, 52).  
 
 
Figure 1.2 The structure of HPV16. [A] Cryo-electron microscopy density map of HPV16. Scale bar 
10 nm. [B] structure of the HPV16 L1 hexavalent pentamer (PDB ID: 5kep) indicated by a blue hexagon. 
Each L1 carboxyl terminus is indicated in magenta, the central β barrel is shown in green. [C] Structure 
of the HPV16 L1 pentavalent pentamer (PDB ID: 5kep) indicated by an orange pentagon. Each L1 
carboxyl terminus is indicated in magenta, the central β barrel is shown in green, while the location of 
surface exposed loops of each L1 chain are indicated by arrows (50).  
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Aside from forming the HPV capsid, the L1 protein facilitates initial attachment and entry into 
host keratinocytes (section 1.5). The minor capsid protein L2, is hidden from the HPV capsid 
surface, although part of the amino terminus (N-terminus) is exposed on the capsid surface 
(52). The position and the exact number of L2 proteins per HPV capsid is inconclusive. 
Evidence suggests that L2 occurs at 1/30th of the abundance of L1, however, some 
researchers suggest 36-72 copies of L2 per HPV capsid (36, 53, 54). Antibody binding studies 
suggest that each L1 pentamer interacts with a single molecule of L2 (i.e., 72 copies of L2 per 
virion), although other biochemical studies suggest a stoichiometric ratio of 5:1, with a total of 
12 L2 proteins associated with 60 of the L1 molecules (54-56). The number of L2 molecules 
per HPV capsid may differ between HPV expression systems, as the L2 gene is often 
transcribed from a codon optimised plasmid with varying expression levels.  
Cryo-electron microscopy (Cryo-EM) analysis suggests that L2 is located at the base of each 
capsomere, (Figure 1.3 [A]). L2 apparently fills the central cavity of each L1 pentamer and 
about sixty N-terminus amino acids may be exposed on the capsid surface (52, 57-59). Two 
other hypotheses exist for the location of L2: one is that L2 is spread throughout the capsid 
within both hexavalent and pentavalent capsomeres, (Figure 1.3 [B]) and the second is that 
L2 is located only at a unique capsomere within the capsid (50, 55, 60). L2 is important for 
viral infection within the host cell (sections 1.4 and 1.6) (61-63). L2 also promotes late gene 
expression and viral DNA encapsulation during virion assembly, leading to infectious HPV 
capsids (53, 64). However, L2 does not appear to form disulphide bonds within the HPV capsid 
and the interactions between L1 and L2 are likely non-covalent and hydrophobic  (52, 54, 65, 
66). This contrasts with several disulphide bonds present within/between the L1 proteins. To 
form the HPV16 capsid, disulphide bonds, especially those formed by cysteines 175, 185 and 
428 in the L1 protein, stabilise individual capsomeres, while disulphide bonds formed by other 
L1 cysteines like cysteine 229 and 379 assist in maintaining overall capsid structure and 
increasing resistance to proteolysis (4, 50, 51, 56, 65, 67, 68). Site-directed mutagenesis also 
suggests that lysine 54, arginine 74, and lysine 82 are needed for successful HPV16 PsV 
assembly (69). Intra-capsomere bonds, forming the pentamers,  are more highly conserved 












Figure 1.3 The possible locations of the HPV16 L2 minor capsid protein.  The HPV L1-only cryo-
electron microscopy map was subtracted from the L1 and L2 containing HPV cryo-electron microscopy 
maps, and putative locations of L2 are indicated as red density. [A] Cryo-electron microscopy map 
indicates L2 is located on the interior of each capsomere. Left panel shows L2 density (red) within the 
internal view of HPV16 capsid (blue). Right panel indicates the L2 density alone (55). [B] High resolution 
of HPV16 capsomeres (grey) indicate L2 density (red) is present primarily around the hexavalent 
capsomere, with some L2 around the pentavalent capsomer. Hexavalent capsomeres are indicated by 






Intercapsomere interactions in papillomaviruses are also stabilised by an ‘invading arm’ 
model, where the L1 C-terminus extends into an adjacent capsomere, forms a loop, and 
returns to the ‘donor’ capsomere (Figure 1.1[B]). The invading portion of the loop runs along 
the floor and up the walls of the canyons between capsomeres. The disulphide bonds formed 
by cysteines 175 and 428 occur at the ‘elbow’ of the invading loop. The L1 N-terminus also 
participates in stabilising the capsomeres, mostly by interactions with other L1 N-terminus 
extensions (4, 50, 51, 56). However, as the HPV capsid is made up of both pentavalent and 
hexavalent pentamers (Figure 1.1 [B] and Figure 1.2 [B, C]), not all intercapsomere contacts 
are identical (48, 50). The intercapsomere contacts between hexavalent and pentavalent 
capsomeres are symmetrical, where a single L1 chain on the pentavalent capsomere (Figure 
1.1 [B]) only contacts a single L1 chain within a neighbouring hexavalent capsomere. 
However, the contacts between two hexavalent capsomeres are dissimilar. Three hexavalent 
capsomere L1 chains contact four neighbouring capsomeres, while the other two L1 chains 
within the hexavalent capsomere contact the remaining two surrounding capsomeres (Figure 
1.1 [B]) (48, 50). 
The HPV capsid encloses an ~8 kilobase (kb) double stranded DNA genome, which is 
associated with host histone proteins (Figure 1.1 [A] and Figure 1.4) (2, 51). The viral genome 
encodes  six ‘early’ (E) regulatory proteins and two structural ‘late’ (L) proteins, within eight 
open reading frames (ORFs) (Figure 1.4) (2, 36, 56). These early and late open reading 
frames are separated by an upstream regulatory region (URR) containing the viral origin of 
replication, which is responsible for the regulation of gene expression, genome replication and 
packaging into progeny virus capsids (2, 70, 71). Polyadenylation signals (AL and AE) for viral 














Figure 1.4  Diagram illustrating the organization of the HPV16 genome and a summary of each 
open reading frames’ (ORFs’) function, as described in the text. The genome contains early (E) 
and late (L) regions. The upstream regulatory region (URR) regulates early ORF transcription. AL and 
AE are polyadenylation signals used during virus transcription (3).  
The early HPV proteins include E1 and E2, which are involved in viral genome transcription 
and replication, while the E5, E6 and E7 proteins are considered oncogenic and facilitate 
malignant host cell transformation (section 1.4) (12, 18, 70, 72). E1 has DNA origin of 
replication (ori) binding and unwinding capabilities, while E2 is a transcription activator. These 
two viral proteins form a complex for enhanced viral DNA replication (2, 72). E2 also has a 
role in viral genome expression, by regulating transcription of the HPV E6 and E7 proteins. 
During viral DNA integration into the host genome, this regulation is lost, leading to 
overexpression of the E6 and E7 viral oncoproteins (18). E6 and E7 are directly associated 
with oncogenesis, as they inactivate two essential tumour suppressor proteins, p53 and 
retinoblastoma protein (pRB) respectively (section 1.4) (2, 3, 18). E4 has a role in viral genome 
amplification, expression of capsid proteins, and virus release (73). The role of E5 in virus 
replication is unclear, although E5 and E6 are involved in immune system evasion (section 
1.4).  
The late proteins of HPV are L1 and L2, which form the icosahedral viral capsid and are 
important during the early steps of host-virus interactions (section 1.5) (71, 74). L2 is also 
important for viral infection within the host cell, facilitating endosomal escape and transport of 
the viral genome to the cell nucleus (sections 1.4 and 1.6) (61-63). Each viral ORF and 
resulting protein successfully functions to allow viral replication and progeny virus assembly. 
This process is highly effective, as the virus alters the host cell machinery to allow greater 
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virion replication. However, this has unintended consequences, enabling metaplastic 
transformation of the host cells, which, if undetected by the host immune system, may cause 
malignant tumorigenesis within the HPV infected tissue. 
 
1.4 HPV infection cycle and malignant transformation of host cells 
The duration of the HPV infection cycle is anywhere from a few weeks to months and is 
dependent on the cell cycling and differentiation of host keratinocytes, although the regulation 
mechanism is unclear (2, 3, 70, 75). In HPV uninfected cervical epithelial tissue, basal 
keratinocytes divide along the basement membrane, while keratinocyte maturation occurs 
vertically, without undergoing further cell division (Figure 1.5, left). HPV is presumed to enter 
the epithelium through micro-abrasions or wounds within the tissue, which expose the basal 
keratinocytes. Infection of basal keratinocytes likely happens while the cells are migrating and 
dividing to repair damage to the epithelium. After successful infection of basal keratinocytes, 
an initial round of viral DNA replication occurs, which maintains the HPV genome as a low 
copy number episome at around fifty to one hundred copies per keratinocyte. This represents 
a latent HPV infection, with no phenotypic changes to the host cell (2, 3, 76, 77). After HPV 
infection, expression of viral proteins causes infected cells to divide vertically, delaying cell 
maturation and epithelial differentiation, while increasing both viral genome replication and 
HPV protein expression (Figure 1.5, right) (2, 71). During progression to cervical cancer, the 
HPV genome is integrated into the host cell genome. This is assumed to be non-random, 
enabling increased cell cycling with the potential for malignant cell transformation by 
destabilising the host genome (2, 70, 77). Moreover, loss of the E2 ORF, during viral genome 
integration, causes dysregulation of the  viral proteins, E6 and E7, resulting in chromosomal 
instability and gene mutations within the host cell genome, further increasing the likelihood of 
oncogenesis (76-78). Interestingly, high-risk HPV types are associated with more genome 
deletions, which may contribute to their greater oncogenic potential (78). 
HPV uses several evasion tactics to avoid detection and elimination by the host immune 
system. For instance, the HPV lifecycle occurs almost entirely within the infected host cell, 
thereby restricting expression of HPV proteins within the underlying epithelial tissue. 
Furthermore, HPV proteins do not cause cell lysis, making antigen detection by the immune 
system difficult. The coupling of the HPV lifecycle to the short lifecycle of host keratinocytes 
further limits the time for HPV detection by the immune system. Moreover, mature virions are 
released from the uppermost layers of the infected epithelium, far away from the immune cells 
circulating within the lower epithelial layers (17, 24, 56, 74, 79-82). Viral proteins may also 
directly affect aspects of pathogen detection by the immune system. E6 downregulates 
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expression of human leukocyte antigen 1 (HLA-1) and E5 also decreases monocyte 
recruitment to the site of infection, allowing the virus to avoid elimination in HPV infected cells 
(2, 83). The E6 protein may also play a role in host immune evasion, by downregulating 
signalling molecules required for interleukin-6 and interleukin-8 expression and type 1 
interferon expression within infected host cells. This prevents recruitment of natural killer cells 
to the HPV infected cells and cell death (17, 18, 82). These immune system evasion strategies 
employed by HPV allow the virus to persist in tissues for long periods (24).  
Once the HPV infected cell enters the upper epithelial layers and exits the cell cycle, there is 
an increase in copies of the HPV genome per cell, with increased expression of viral genes 
and proteins (Figure 1.5; right) (2, 3, 77). Viral DNA replication is dependent on the host cell, 
as the virus only encodes a single DNA replication enzyme, E1. Consequently, other HPV 
proteins function to induce viral DNA synthesis, inhibit cell growth regulation signals, prevent 
apoptosis, and delay host cell differentiation (2, 3, 76).  Although a host cell’s progression to 
a malignant state is a non-productive infection for HPV, the overexpression of HPV proteins 
and the proteins’ effects on infected keratinocytes aids in malignant transformation of cells 
(70, 78). Central to oncogenesis are the viral proteins E6 and E7. E6 binds the host protein 
p53, a key cell protein for the regulation of the cell cycle, DNA repair and apoptosis, leading 
to cell cycle disruption and promotion of cell proliferation. E6 also prevents apoptosis, by 
interfering with the activities of pro-apoptotic proteins and preventing telomere shortening, 
extending the lifespan of the infected cell. This may increase the likelihood of spontaneous 
gene mutations, which accumulate and lead to tumorigenesis (2, 3, 18). The E7 oncoprotein 
binds to unphosphorylated cellular retinoblastoma (Rb) protein, which overrides the G1/S 
checkpoint of the cell cycle, leading to increased cell division (3). E7 also interacts with cell 
proteins like p21, which allows the infected cell to bypass cell cycle checkpoints, leading to 
cell proliferation and potentially oncogenesis (2, 3, 18, 84).  
Although the expression of viral proteins causes increased cell cycling with the potential for 
carcinogenesis in infected tissue, the primary function of the viral proteins is to enable the 
increased production of progeny virions within infected host cells. During progeny virion 
assembly, the HPV genome replicates in the nucleus and L1 and L2 capsid proteins are 
assembled in the cell cytoplasm. L2 then localises into promyelocytic leukaemia (PML) bodies 
within infected cells before recruitment of L1 proteins and viral DNA with cellular histones, 
assembling into the native HPV, This progeny virus is then released from the most superficial 
epithelial layers (Figure 1.5, right) (53, 64, 70, 85). After release from the epithelium, progeny 




Figure 1.5. Diagram of the HPV lifecycle in the epithelium. The layers of the epithelium are indicated 
on the far left. HPV (red hexagon) infects basal keratinocytes exposed through mico-abrasions, 
indicated by the gap between the epithelial layers and the arrow. HPV uninfected epithelium is shown 
on the left (‘normal’ epithelium; purple) and HPV infected epithelium is on the right (‘HPV infected 
epithelium’; yellow). The lifecycle of HPV is indicated in brief on the right, beginning with early gene 
expression within the basal epithelium, followed by late gene expression and viral genome amplification 
in the upper layers. Finally, the progeny virion is assembled and shed in the upper epithelial layers (86). 
                                                                                                 
1.5 HPV transmission and entry mechanisms 
HPV is spread by direct skin-to-skin contact and enters the basal epithelium through micro-
abrasions in the tissue (Figure 1.5), initially binding to the basement membrane followed by 
transfer to the basal keratinocyte surface (17, 80, 87). The different HPV types are 
epitheliotropic, only successfully infecting mitotically active basal keratinocytes in the 
epithelium of the skin, the genital and oral mucosa (2, 3, 6, 88). This strict cell tropism is 
suspected to be dependent on events following HPV entry into cells, as HPV5, a non-genital 
HPV type can infect genital tissues but less effectively than either HPV16 or 18, which infect 
genital tissues (6, 74, 89). The limited cell tropism is also closely linked to keratinocyte 
differentiation (section 1.4 and Figure 1.5) (2, 36, 80, 85).  
 
Like many viruses, HPV may use a co-ordinated multi-receptor entry process, initially binding 
to a low-affinity receptor present on many cell types, before transfer to a more specific entry 
receptor (47, 90). Papillomaviruses likely use an evolutionarily conserved binding receptor or 
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receptor complex, as bovine papillomaviruses (BPV) and HPV compete for binding to the cell 
surface, while Simian Virus 40 (SV40), does not interfere with HPV binding (59, 89). Early 
studies reported a specific HPV attachment receptor with many copies on the cell surface, and 
clusters of virus-like particles (VLPs) were observed attached to HeLa cells, rather than VLPs 
binding evenly to all areas of the cell surface. VLP binding increased until apparent receptor 
saturation, as increasing the amount of VLPs available did not affect further VLP binding (59, 
89). Importantly, HPV binding was found to be trypsin sensitive, indicating a membrane protein 
may be used by HPV for cell attachment (89).  
 
1.5.1 Heparan sulphate proteoglycans as the initial cell surface receptor for 
HPV 
Heparan sulphate proteoglycans (HSPGs) on the basement membrane and keratinocyte 
surface are the likely initial cell binding receptor for most oncogenic HPV types in vitro and in 
vivo, including HPV16 and 18 (47, 53, 90-92). HSPGs are complex, negatively charged 
glycoproteins containing covalently bound heparan sulphate chains. These heterogenous 
molecules are present on the cell surface and extracellular matrix (ECM), and act as receptors 
for cytokines, chemokines, and growth factors (93, 94). They are also receptors for selective 
cellular proteases, regulating the activity of these enzymes and their distribution in the ECM. 
Therefore, HSPGs are involved in numerous cell processes, including wound healing, cell 
signalling, cell motility and endocytosis (6, 93, 94). HSPGs are expressed in high numbers on 
epithelial cells, the natural host cell for HPV (6, 69, 90, 95, 96). Moreover, many other viruses 
make use of HPSGs as an initial non-specific cell binding receptor, and HPV seems to be no 
exception to this (94, 96-98). Since protein binding to HSPGs on the cell surface prevents 
protein degradation by extracellular proteases, HPV attachment to HSPGs may also function 
to inhibit virus degradation prior to entry. HPV may also use HSPGs to mediate proteolytic 
processing by specific proteases necessary for successful entry (section 1.5.3) (94, 99).  
To demonstrate the involvement of HSPGs in HPV binding, inhibition of cell 
glycosaminoglycan (GAG) synthesis or virus incubation with cells deficient in cell surface 
GAGs was found to reduce HPV VLP binding to cells (47, 92, 96, 100). Treatment of HaCaT 
(spontaneously transformed human keratinocytes), COS-7 (green monkey derived fibroblast-
like cells) and primary human keratinocyte cells with heparinase and sodium chlorate (to 
disrupt cell surface heparan sulphate structure and charge) drastically reduced HPV11, 16, 
31 and 33 VLP binding (47, 79, 95, 96, 100, 101). Similarly, HPV11 VLP binding to HaCaT 
and COS-7 cells was inhibited when the VLPs were incubated with HSPG binding competitors, 
including heparin (section 1.5.1.1) and protamine, suggesting the virions bound to these 
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HSPG binding competitors, rather than the cell surface HSPGs. A compound binding to 
heparan sulphates, a N,N′-bisheteryl derivative of dispirotripiperazine (DSTP27), prevented 
HPV16, 18 and BPV1 infection of transformed human embryonic kidney (HEK) 293TT cells 
(47, 79, 92). Moreover, x-ray crystallography and cryo-electron microscopy studies have 
directly indicated that HPV16 and HPV18 bind to sulphated glycoproteins (50, 102, 103). 
These studies all indicate a role for cell surface HSPGs for HPV binding during infection. 
However, HPSGs as the initial HPV binding receptor has also been challenged, as HPV31 
virions derived from organotypic raft culture bound to cells independently of HSPG expression 
(104). Likewise, HPV16, 18, 31 and 45 organotypic raft culture derived virions had differing 
dependencies on cell surface sulphated GAGs. Alternatively, the virions could make use of 
several HSPGs on the basement membrane and/or cell surface to mediate infection (41, 102, 
103). In line with this hypothesis, Johnson et al. found that HPV16 must bind to HSPGs present 
on both the basement membrane and cell surface within the female murine genital tract for 
successful infection in vivo, indicating HPV binds to several different HSPGs on the cell 
surface and basement membrane during a natural infection (6). 
The exact HSPG type used by HPV during entry is unknown and may differ depending on the 
infection system used (6). Current estimates are that somewhere between 1X104 and 2X104  
HPV entry receptor molecules are present on epithelial cells, while there are many more (~106 
) proteoglycans of different types on the cell surface (47, 89, 96, 105). Candidate HSPGs for 
HPV entry are the cell membrane bound HSPGs (syndecans and glypicans) or the secreted 
ECM HSPGs (agrins and perlecans) (94). Syndecan-1 and syndecan-4 are 31-45 kDa 
glycoproteins with covalently attached chains of heparan sulphate and/or chondroitin sulphate. 
Glypican-1 and glypican-4 are two 57-69 kDa glycoproteins with covalently attached heparan 
sulphate chains. These HSPGs are all expressed on the extracellular matrix of epithelial cells 
and fibroblasts, cell types known to facilitate productive HPV infections (47, 94).  
To investigate which HSPG facilitates HPV16 VLP binding, keratinocytes were incubated with 
increasing heparinase concentration to remove cell surface HSPGs, or phosphatidylinositol-
specific phospholipase C (PI-PLC) to specifically remove glypicans. Heparinase reduced VLP 
binding in a dose dependent manner, while PI-PLC did not, implying glypicans are not the 
HSPG type used during VLP binding to keratinocytes (69, 100). Syndecan-1 may be the 
primary HSPG used by HPV16 VLPs for infection in vitro, as cells deficient in most cell surface 
HSPGs, but expressing transfected syndecan-1 had the greatest HPV VLP binding capacity, 
compared to cells transfected with either syndecan-4 or glypican-1. Moreover, syndecan-1 
was the primary HPV binding HSPGs on keratinocytes infected with HPV11 and BPV (47, 
100). Syndecan-1 is also associated with infection by other pathogens and is a co-receptor for 
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many of the growth factor receptors that HPV makes use of during infection (section 1.5.3), 
making this HSPG type the likely HPV receptor (94, 106).  
However, other research suggests that the different HPV types have a more complex 
dependency on cell surface glycosaminoglycans than described above. In the presence of 
chondroitin sulphate, HPV18 virions were non-infectious, while HPV16, 31 and 45 were able 
to infect cells. Furthermore, adding exogenous carrageenan (a sulphated polysaccharide 
derived from algae) did not inhibit HaCaT cell infection with HPV16 and HPV31, but did inhibit 
infection with HPV18 or HPV45 (107). Potentially, HPV binds to more than a single HSPG 
type and recruits other HSPGs for binding during a sequential entry process, or there may be 
redundancy in the HSPG used by HPV during entry (6, 41, 90, 96, 102, 103, 107). Another 
possible explanation for the interaction between HPV and cell surface HSPGs is that HPV 
may not dissociate from HSPGs on the cell surface during entry but instead the capsid 
becomes coated with HSPG shed from the cell surface, followed by subsequent internalisation 
of the HSPG coated capsid (108).  
 
1.5.1.1 Heparin binds to HPV experimentally but is not involved in HPV infection 
As HSPGs are long and heterogenous molecules which are difficult to synthesise, heparin (a 
related anionic sulphated polysaccharide) is often used to study the interaction between 
HSPGs and HPV during infection. Notably, heparin is not involved as a cell binding receptor 
in the natural HPV infection but is used as an in vitro substitute for HSPGs (6, 41, 50, 79, 94, 
102, 103). 93% of HPV11 VLPs can be eluted by free heparin, and HPV types 16, 33, and 39 
were found to bind efficiently to a heparin-bovine serum albumin (BSA) complex compared to 
control BSA. Adding exogenous heparin had an inhibitory effect on HPV11 and 16s’ ability to 
infect HaCaT and COS-7 cells (47, 79, 96, 101). A similar inhibition was observed for HPV 16, 
18, 31, 45, 58, 59 and 68 pseudovirion infection of COS-7 cells (95). Low concentrations of 
heparin (0.05 mg/mL) abolished infectivity of HPV16 and HPV33 pseudovirions, whereas this 
inhibitory effect was not seen with other glycosaminoglycans (96). When heparin was added 
to HaCaT cells before adding pseudoviruses, HPV binding did not decrease (101). This implies 
that heparin obstructs HPV binding to HSPGs by binding to the virus capsid, rather than the 
cell surface. Increasing concentrations of heparin decreased HPV VLP binding to cells in a 
dose-dependent manner, with 50% inhibition observed at the lowest heparin concentration 
(0.25 g/ml) and complete inhibition at 32 g/ml heparin, similar to results obtained with HPV11 
VLPs (47, 69, 100). Together, these studies indicate that several HPV types bind to heparin, 
and heparin competes with the cell surface HSPGs for binding sites on the HPV capsid. This 
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confirms the suitability of heparin as a substitute for HSPGs when studying HPV entry 
mechanisms. 
However, HPV’s sensitivity to heparin may differ depending on the HPV production system 
used. When organotypic raft-culture derived HPV was used to bind to or infect HaCaT cells, 
the various HPV types had different responses to the presence of heparin. HPV16 was able 
to attach to the cell surface in the presence of heparin, while HPV31, an evolutionarily related 
HPV type was unable to bind to the cell surface. Likewise, HPV18 and a related type, HPV45, 
were unable to bind HaCaT cells (107). These results suggest that HPV16 may make use of 
a non-HSPG receptor, while other HPV types make use of sulphated polysaccharides for 
binding. However, the viruses had dissimilar responses to infection in the presence of heparin. 
HPV16 and HPV31 infection of HaCaT cells was unaffected by heparin. Similarly, HPV45 
infection was resistant to heparin, while a related type, HPV18, was inhibited by heparin (107). 
The discrepancy in the effect of heparin between organotypic derived or pseudovirion 
production HPV particles may be explained by the presence of cellular factors and proteases, 
which are necessary for infection (see 1.5.2), being present in the differentiating tissue culture, 
while being mostly absent from the pseudovirus system. Accordingly, the differentiating tissue 
derived virions may be processed by these cellular factors prior to cell infection, allowing them 
to bypass the initial HSPG attachment step during infection and resulting in resistance to 
heparin binding (87, 99, 104, 106, 109, 110). Interestingly, mutations in L1 surface exposed 
amino acids on the HPV16 capsid implicated in cell surface binding (section 1.5.1.2) display 
decreased cell binding when incubated with heparin, suggesting that specific amino acids 
allow HPV binding to HSPGs on the cell surface (69).  
 
1.5.1.2 Surface exposed amino acids of L1 mediate HPV attachment to heparan 
sulphate proteoglycans 
HPV attachment to HSPGs (or heparin) may be facilitated by the L1 viral capsid protein, as 
the C-terminus of L1 in HPV16 and HPV11 interacts with glycosaminoglycans, and 
neutralising antibodies against L1 inhibited HPV16 VLP’s attachment to keratinocytes (47, 50, 
69, 79, 100, 105, 111). Two of these antibodies, H16.V5 (V5) and H16.U4 (U4), bind to 
different areas of L1 HPV16, thereby preventing infection. V5 binds to a conformational 
epitope at the top of the L1 pentamers and prevents virus attachment to the underlying 
extracellular matrix (ECM) but HPV may still bind cell surface HSPGs. Similarly, an x-ray 
crystallography structure of the L1 only pentamer, complexed with heparin found that heparin 
only bound to surface-exposed regions of the pentamer, despite all regions being physically 
accessible for binding (102). U4 recognizes a linear epitope within the C-terminal arm of L1 
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that forms the “invading arm” and permits virus binding to the ECM while blocking binding to 
cell surface HSPGs (105, 111, 112). Consequently, the L1 regions bound by these antibodies 
identified either on the surface of the L1 proteins, or within the L1 C-terminus “invading arm” 
are necessary for HPV binding to HSPGs on the cell surface. 
The L1 C-terminus is well conserved among HPV types and is characterized by a cluster of 
six to eight basic amino acids within the final fifteen residues and a shorter three to four basic 
amino acid cluster upstream. The putative heparin or HSPG binding motif is BBBXB where B 
is a basic amino acid (lysine or arginine) residue, and X is any amino acid. Potentially the L1 
C-terminus in the canyon between capsomeres is the site for HSPG binding (47, 52, 69, 94) 
(94). Site-directed mutagenesis indicated that lysines 278, 356, and 361 on L1 were essential 
for both cell surface binding and infectivity with HPV16 PsVs composed of both L1 and L2 
capsid proteins (69). A combination of these lysine mutations had a greater effect than single 
mutations, while the triple mutant had the least binding and infection capacity, suggesting that 
these lysines bind HPV to the cell surface in a co-operative manner (69).  
However, mutation of arginine amino acids in the vicinity of these three lysines had little effect 
on HPV16 PsV binding and infectivity, implying HPV cell binding and infectivity was dependent 
on charge distribution within the binding area, rather than a specific amino acid sequence (47, 
69). Structural studies indicated that lysines 54, 56 and 356 with threonine 266 and arginine 
285 from two neighbouring L1 monomers bind heparin. Additionally, heparin was also found 
to bind asparagines 57 and 450 and lysines 59, 443 and 452 in another binding patch on the 
pentamer surface. This study also demonstrated that heparin (and potentially HSPGs) binds 
to either positively charged or polar residues, which would allow charge-charge interactions 
and hydrogen bonds to form with the anionic heparin molecule(s) (90, 102, 103, 113, 114). 
However, during HPV33 infection, the L1 C-terminus was not required, as a peptide composed 
of HPV33 L1 C-terminus amino acids did not inhibit HPV33 infection, even at a high 
concentration (5 mg/mL). Furthermore, antiserum directed against this peptide had no effect 
and HPV33 particles without some L1 C-terminus amino acids still bound to heparin-coated 
ELISA plates, suggesting that the L1 protein of HPV33 is not involved in cell surface binding 
(96). Moreover, heparan sulphate molecules inhibited HPV binding and infection, but other 
proteoglycan molecules with similar numbers of negatively charged residues did not inhibit 
HPV infection, suggesting the interaction between HSPGs and virions could depend on 
structural features, rather than electrostatic interactions on HSPGs (93). Further studies will 
be needed to investigate whether this applies to other HPV types too.  
The minor L2 capsid protein does not seem to be involved in initial cell surface binding as BPV 
VLPs, composed of either the L1 capsid protein or both capsid proteins (L1 and L2) were 
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equally effective at inhibiting native BPV binding. Additionally, L1-only HPV33 VLPs still bound 
to HeLa cells, without the need for the L2 protein (59, 89). Antisera against L2 did not affect 
the ability of BPV to bind to cells but affected infectivity and L1 only PsVs were much less 
infectious than L1/L2 HPV pseudovirions. This research implies that L2 is not involved in cell 
surface binding but is involved in later stages of infection (58, 59). 
1.5.2 Conformational changes to the HPV capsid during entry 
As detailed above, HPVs are suggested to use HSPGs as an initial non-specific contact to the 
host cell, which is followed by virus conformational changes and transfer to an entry receptor 
or receptor complex. Several proteins are proposed as necessary for productive infection, 
some of which may facilitate changes in the HPV capsid structure, including cyclophilin B, 
kallikrein-8 and, most notably, furin (section 1.5.3). Furin is a 96 kDa multidomain proprotein 
convertase, with a vital responsibility for converting proteins including integrins, 
neuropeptides, growth factors and hormones into their mature forms, which then participate 
in homeostasis, cell signalling,  and embryogenesis (115-118). Furin contains a highly 
negatively charged catalytic site, which cleaves protein precursors with the amino acid 
sequence – arginine/lysine-X-X- arginine/lysine where the first and last amino acid can either 
be arginine or lysine, and X is any amino acid. The HPV L2 capsid protein contains a furin 
cleavage site on the N-terminus, at arginine 12, which is highly conserved across 
papillomavirus species (106, 110, 116, 118).  
This furin cleavage site was demonstrated to be functionally relevant in HPV16 and BPV1 
infection, as mutated arginine amino acid residues resulted in reduced HPV infection levels 
(106). Furin is widely expressed in mammalian tissues and is present both intracellularly, in 
the trans-Golgi network, on the cell surface and extracellularly (87, 115, 116, 118, 119). These 
properties allow the enzyme to be exploited by pathogens during entry to enhance infectivity 
and pathogenicity, including bacteria like Bacillus anthracis, Clostridium septicum and many 
viruses, such as avian influenza, HIV-1, semliki forest virus, equine herpesviruses, 
cytomegaloviruses, ebolaviruses and SARS-CoV2. The glycoproteins of these viruses must 
be processed by furin to form mature virions and to enhance infectivity (97, 115, 118-125). 
While furin is generally membrane-bound, an active form can be secreted, but it is presently 
unknown whether furin is membrane-bound or the soluble when the enzyme acts on HPV16 
particles during natural HPV infection (105). However soluble furin can cleave the L2 minor 
capsid protein, making this form of furin sufficient for infection in vitro (105, 126). 
Proteolytic processing of L2 by furin is a rate-limiting step during HPV entry, indicating the 
importance of this step for HPV infection (105). If L2 is not cleaved during entry, L2 and the 
viral genome fail to escape the endosome during intracellular trafficking (section 1.6) and the 
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virus is non-infectious (106). Treatment of HPV5, 6, 16, 18, 31 and BPV PsVs with an inhibitor 
of furin and related proteases prevented infection in HeLa cells. This was not the case with 
inhibitors of other proteases, indicating furin or a furin-like protease was necessary for infection 
(106). To confirm this finding, HPV16 PsVs and BPV1 virions were incubated with two furin 
deficient cell lines: FD11 (Chinese Hamster Ovary (CHO)) cells, and LoVo (colon carcinoma) 
cells. These cells were entirely resistant to either papillomavirus infection, even though the 
cells may express other non-furin proprotein convertases (106). Similarly, HPV16 PsVs which 
were incubated with exogenous furin prior to cell infection do not need cellular furin for 
infection in vitro or in vivo, hence exogenous furin successfully processed the virus capsid for 
entry (99, 105, 126, 127). This was further confirmed by incubating either furin processed or 
furin unprocessed virions in the presence of a furin inhibitor before cell infection. The furin 
inhibitor only prevented infection of the furin unprocessed virions, presumably by preventing 
the proteolytic activity of cellular furin on these HPV capsids (105, 126, 127). Moreover, 
HPV16 PsVs are much more infectious when cleaved by exogenous furin, compared to 
uncleaved HPV, demonstrating the vital role of furin in enhancing the infectivity of HPV (126).  
Furin likely acts on the HPV capsid at the cell surface as inhibition of several endosomal and 
lysosomal proteases, had little effect on infection, while in vivo, cleavage of L2 may occur on 
the basement membrane (87, 106, 112). Furin processing is thought to occur near the exterior 
of L1 pentamers on the HPV capsid, as an L1 specific antibody (H16.V5) which binds to 
surface loops on the L1 pentamer, blocked furin cleavage of L2 (112). In contrast, another L1 
specific antibody (H16.U4), which binds to ‘invading arms’ around HPV capsomeres (magenta 
in Figure 1.2) had little effect on L2 cleavage, suggesting that the furin cleavage site, 
comprising part of the L2 N-terminus, is unlikely to be located in the ‘canyons’ between 
capsomeres (112). Interestingly, an L2 specific antibody enhanced furin cleavage of L2. 
Potentially, the antibody prevents its’ L2 epitope from being buried after antibody binding, 
increasing furin’s’ accessibility to the cleavage site on L2 (112). Furin appears to incompletely 
cleave HPV L2 as several research groups have demonstrated about 50% cleaved L2, with 
some uncleaved L2 detected within the late endosome of infected cells (106, 112, 126, 127). 
However, it is unknown at present whether this percentage of virions is completely furin 
cleaved within the total HPV population, or whether all the HPV L2 molecules are partially 
cleaved across the entire virus population (112). This situation may represent a natural 
infection, with heterogenous HPV capsids having differing degrees of exposure of the L2 N-
terminus and susceptibility to furin cleavage (112, 127). Even though L2 is partially cleaved 
by furin, there is evidence that the HPV capsid undergoes changes to the capsid quaternary 
structure to enable successful infection (87, 112, 127, 128).  
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This conformational change after furin cleavage has been demonstrated indirectly by antibody 
binding studies using the RG-1 antibody, which detects the amino acids 17-36 on the L2 
protein, which are adjacent to the furin cleavage site. L2 exposure of the N-terminus was 
assessed by RG-1 detection of a human influenza hemagglutinin (HA) tag inserted at the 
extreme N-terminus of the L2 protein. Antibody binding to this HA-tagged N-terminus of the 
L2 HPV protein increased over time, indicating greater exposure of the L2 N-terminus while 
RG-1 is unable to bind to furin uncleaved HPV16. Although the L2 N-terminus is partially 
exposed on the capsid surface (52), this result suggests these amino acids only become 
surface exposed after furin cleavage. Immunofluorescence staining also demonstrated that 
the L2 amino acids 17-36 were exposed over time after HPV16 PsV binding to the basement 
membrane (105, 127, 128). This suspected conformational change was confirmed by 
immunoprecipitation, where the RG-1 antibody was able to bind furin cleaved HPV16 particles, 
but not furin uncleaved particles (87, 127). Likewise, HPV capsids which have undergone a 
maturation step are in a different capsid conformation compared to immature capsids and are 
resistant to furin cleavage. This implies that the furin cleavage site is unavailable until the viral 
capsid is in a conformation similar to that of immature virions (106). Furthermore, treatment of 
HPV16 PsVs bound to HaCaT cells with a furin inhibitor prevented exposure of the RG-1 
antibody binding site on L2 (128). 
Furin mediated exposure of the L2 protein is necessary for internalisation and intracellular 
infection steps after cell surface binding (58, 106, 110, 129, 130). Full length HPV16 L2 capsid 
proteins weakly bound to HeLa cells, while a peptide made up HPV16 L2 protein residues 13 
to 31 had greater binding to cervical cancer cell lines (131). None of the other peptides made 
up of other regions of the L2 amino acid sequence bound HeLa cells, emphasising the 
importance of the region near the furin cleavage site for cell surface binding (131). However, 
other studies have found that HPV16 L2 peptides made up of the first twelve amino acids in 
L2, adjacent to the furin cleavage site, did not inhibit HPV16 PsV infectivity of COS-1 cells 
(58). COS-1 cells are non-human and non-keratinocyte cells and may not represent the most 
appropriate cell line for assessing HPV16 infectivity, given the strict virus cell tropism. 
Importantly, it cannot be excluded that these L2 peptides are internalised by cell endocytosis, 
rather than the internalisation pathways used by HPV. Interestingly, heparinase treatment of 
HeLa cells reduced L1-only HPV16 VLP binding, but not the L2 peptide binding, suggesting 
that HPV16 uses the L1 protein to attach to HSPGs on the cell surface, before L2 binding to 
a non-HSPG receptor (131). However, HPV16 L1/L2 virions were unable to bind heparinase 
treated HeLa cells, suggesting that the region of the L2 peptide which bound to HeLa cells is 
inaccessible for initial binding (131).  
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Currently, it is proposed that changes to the HPV capsid after interaction with host molecules 
needed for infection, occurs mainly to the L1 capsid protein, given that this is the predominant 
capsid protein and conceals the bulk of the L2 minor capsid protein (50, 55, 60). It is likely that 
L2 also undergoes some structural rearrangement after these processing steps, but this is 
difficult to identify as the location and the exact number of L2 molecules per HPV capsid is 
inconclusive. Indeed, two L1 specific antibodies which bind conformational epitopes on the L1 
protein (H16.V5 and H16.E70) prevented exposure of the RG-1 L2 antibody binding site on 
HPV16 PsV capsids, suggesting the L1 capsid protein occludes the RG-1 antibody binding 
site. This is unlikely to be due to steric hindrance between the two antibodies, as cell bound 
HPV16 virions were able to bind both L1 and L2 specific antibodies. Consequently, the two L1 
specific antibodies prevent the cell surface conformational change necessary for furin 
cleavage and L2 antibody binding site (128).  
The conformation change to L1 may also be caused by a keratinocyte secreted enzyme, 
serine protease kallikrein 8 (KLK8)  which processes L1 before cell entry (132). Similarly, 
another host protein, cyclophilin B may cause a conformational change in the viral capsid, 
although the effects of cyclophilin B on HPV entry is debated. Potentially cyclophilin B is 
essential for intracellular infection steps rather than HPV entry (53, 105, 112, 133). HPV33 L1-
only and L1/L2 VLPs were incubated with two antibodies specifically recognising L1 epitopes 
on capsomeres, H33.B6 and H33.J3. The antibody-coated VLPs were then exposed to 
heparin. H33.B6 impaired VLP binding to heparin while H33.J3 did not impair VLP-heparin 
contact, suggesting these antibodies prevent HPV33 infection through different mechanisms 
(93). H33.J3 neutralised cell bound but not free virions, suggesting the H33.J3 epitope is only 
available on HPV33 after cell attachment and a capsid conformation change. Interestingly, 
this antibody has similar characteristics to a BPV antibody, which binds to hexavalent 
capsomeres, neutralising infection without affecting cell binding (93). Potentially after cell 
surface binding, a conformation change within the hexavalent capsomere allows H33.J3 
binding to the HPV capsid. This is somewhat likely, as HPV and BPV capsid proteins are 
functionally conserved (131).   
The proteolytic steps by host molecules and conformational changes to the HPV capsid are 
thought to be necessary for HPV transfer to the unknown secondary receptor or receptor 
complex (section 1.5.3), and viral entry into host cells (6, 87, 99, 101, 110). The process of 
HPV entry into host cells is very slow and this may be due to the number of conformational 
changes and interactions with the host cell and associated proteins for successful entry (59, 
105). However, the effects of furin cleavage on the HPV capsid and the proposed capsid 
conformation changes cannot be seen by negative staining and low-resolution electron 
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microscopy (EM) (126, 127). Consequently, high-resolution imaging of furin cleaved particles 
is necessary to directly determine whether furin cleavage of L2 leads to conformation changes 
in the HPV capsid, as proposed in the literature.  
 
1.5.3 HPV co-receptors for binding and entry 
HPV pseudovirions’ interaction with the cell surface changes from heparin sensitive to heparin 
resistant, which may indicate the presence of a secondary receptor (96). Other evidence for 
the presence of a second, more specific entry receptor is that combined inhibition of two 
molecules proposed as HPV binding and/or entry receptors, heparan sulphate and laminin 
332,  did not completely abolish HPV16 PsV infection of HaCaT cells (92). Additionally, HPV16 
PsVs were unable to infect pgsA-745 cells, which are deficient in cell surface HSPGs. 
However, these cells could be infected when exogenous furin, a protease necessary for 
infection (sections 1.5.2 and 1.5.3) was added to the virions, allowing these virions to bypass 
the HSPGs and enter the cell through unknown mechanisms. As the virions could infect cells 
in the absence of HSPGs, the presence of a second, non-HSPG receptor responsible for HPV 
uptake was proposed (99). Virion transfer to the elusive secondary receptor is slow, and this 
may be for several reasons: the affinity for the secondary receptor may be low, there may be 
few secondary receptors available for binding on the cell surface and/or there are few binding 
sites available on the HPV capsid (90, 105). Several cellular molecules are proposed as either 
entry or co-receptors for HPV internalisation such as α-integrins, tetraspanins, epithelial 
growth factor receptor (EGFR), keratinocyte growth factor receptor (KGFR), and annexin A-2. 
These host molecules may act co-operatively to enable HPV infection, as no single receptor 
was sufficient for HPV infection (36, 53, 82, 108, 134, 135).  
Integrins recognize short peptide sequences present on many ECM proteins, and binding 
leads to activation and intracellular signalling (101). HPV16 VLP binding was found to correlate 
with α-integrin expression, with HaCaT keratinocyte and cervical cancer cells having the 
greatest integrin expression and HPV16 binding, while non-keratinocytes had low levels of 
both integrin expression and HPV binding. Therefore, integrins may be a factor in the restricted 
cell tropism demonstrated by HPV. Treatment of HaCaT cells with an α6 integrin monoclonal 
antibody reduced HPV6b VLP binding, and HPV types 6b, 18, 31, 35 and BPV1 were found 
to induce intracellular signalling upon binding to integrins. These studies indicate a direct 
interaction between integrins and HPV (136, 137). However, increased β integrin expression 
on cells did not correlate with HPV16 VLP binding, and antibodies directed against non α-
integrin types did not inhibit HPV binding, suggesting α-integrin are the integrin type used 
during HPV infection (136, 138). HPV may use the L1 protein to bind α-integrin as both L1 
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only and L1/L2 VLPs could induce signaling (137). Interestingly, cell surface-bound HSPGs 
co-operate with integrins, allowing cell attachment to the ECM, cell-cell interactions and cell 
motility (94). Potentially, HPV uses this interaction to form a receptor complex with cell surface 
HSPGs for entry into the cell, which could explain why no single secondary receptor has yet 
been identified (108). In contrast, other work has demonstrated that HPV entry may be integrin 
independent, suggesting that other cellular factors are more important for HPV entry (79, 96, 
100).   
Keratinocytes infected with HPV16 virions displayed colocalization with tetraspanins CD63 
and CD151 on the cell surface of HeLa cells, implying that tetraspanins may be an HPV cell 
surface receptor. However, CD151 siRNA knockdown did not diminish HPV16 PsV binding to 
HeLa, HaCaT or primary human keratinocytes but did inhibit HPV16 PsV infectivity. This 
indicates that tetraspanins may function during intracellular steps in HPV infection. Likewise, 
only HPV PsVs associated with CD151 were found intracellularly (139, 140). Similarly, HPV 
may use growth factors and their receptors for internalisation, as demonstrated for EGFR and 
KGFR on the plasma membrane of HaCaT cells, leading to rapid activation of the growth factor 
receptors and subsequent activation of their cell signalling pathways (108). No single growth 
factor receptor was proposed to be responsible for HPV entry. When EGFR and KGFR were 
added to serum-free medium, HPV16 infection of HaCaT cells was restored, further indicating 
that growth factors are important receptors for HPV during infection (108).  
Another surface protein suggested to be involved in HPV infection is annexin-A2, which was 
found to be present on both HeLa and HaCaT cells. An annexin-A2 antibody reduced HPV16 
PsV binding to both keratinocyte cell lines, while shRNA knockdown of annexin-A2 reduced 
HPV16, 18, 31 and 45 PsV binding to HeLa cells. Moreover, re-expression of annexin-A2 in 
these cells restored HPV16 PsV infectivity. Co-IP confirmed an interaction between HPV16 
PsVs and annexin-A2, which may be mediated by the HPV L2 protein, as the L2 amino acids 
from 108 to 126 bound annexin-A2, suggesting L2 may be functional in HPV entry (141, 142).  
Given the above evidence, it is well established that, after initial HSPG binding, HPV is 
prepared for entry and intracellular infection steps by several host factors including cyclophilin 
B, kallikrein 8 and furin, before transfer onto a  single or several secondary entry receptor(s).  
 
1.6 HPV internalisation and trafficking 
HPV internalisation into host cells is a slow process and is presently thought to occur by a 
process similar to macropinocytosis, as the process is dependent on actin dynamics, Na+ /H+ 
24 
 
exchangers, P21 activated kinases (PAK-1) and protein kinase C (PKC) signalling (59, 89, 
134, 143, 144). Interestingly, actin is also necessary for internalisation of cell surface HSPGs, 
the initial HPV receptor. Potentially, HPV also makes use of this pathway to enter the cell 
(145). This idea was confirmed when HPV was internalised into a non-infectious cellular 
pathway in the presence of the actin-depolymerizing drug cytochalasin D, suggesting that 
intact actin filaments are required in early events during HPV entry (92). Further, HPV31 
virions were found to cause cytoskeletal rearrangements and filopodia formation on HaCaT 
cells which was activated by tyrosine kinase and phosphoinositide 3 (PI3)-kinase signalling 
pathways (146). HPV31 infection of HaCaT cells was inhibited by inhibitors of tyrosine kinases, 
PI3 kinases, actin polymerization, and microtubule polymerization and the viruses remained 
on the cell surface. In contrast, during HPV31 infection of untreated cells, the viruses were 
detected in the nuclear region. This reinforces the notion that these cell processes are 
important for HPV internalisation and trafficking (134). However, HPV internalisation is 
independent of clathrin, caveolin, cholesterol and dynamin (105, 134, 143, 144).  
After internalisation, HPV is trafficked through the cell cytosol in endosomal compartments, 
and the acidification of late endosomes allows viral capsid uncoating. This process may 
require annexin-A2. L2 complexed with the HPV genome escapes the endosome and travels 
to the nucleus via the trans-Golgi network (113, 142-145). Endosomal escape is reliant on 
successful furin cleavage of L2 and requires several cellular proteins including γ-secretase 
and sorting nexin 17 (144)  (147-149). Cyclophilins within the host cell facilitate detachment of 
the L2 capsid protein with the viral genome from the HPV capsid during capsid disassembly 
(150). Following this, the L2 viral genome complex travels through perinuclear compartments, 
which requires an interaction between L2 and the dynein microtubule network (143, 145, 151, 
152). The process of nuclear entry by the viral genome is unclear, although it does involve L2 
and the viral genome co-localising with nuclear import proteins, nuclear domain 10 (ND10) or 
promyelocytic leukaemia (PML) bodies, with nuclear envelope breakdown (105, 144, 153, 
154). Cell cycle progression may be necessary for successful HPV infection (75). This is likely 
as the infectious cycle of HPV is closely linked to that of its’ host cell. A summary of the entry 



















Figure 1.6. Schematic of entry mechanism used by HPV16 for successful infection.  HPV16 
binds to heparan sulphate proteoglycans (HSPGs)  present on the extracellular matrix or cell surface. 
Epidermal growth factor and keratinocyte growth factor may also be activated upon cell surface 
binding and begin intracellular signalling cascades for virus internalisation. After HPV binding to the 
cell surface cylophillin B may cause a conformation change in the capsid protein, exposing the N-
terminus of L2. HPV16 may also bind to α6-intergrin, initiating an intracellular singalling cascade. 
HPV16 then transfers to the secondary receptor (complex) and is internalised via clathrin- caveolin, 




1.7 Challenges of studying HPV infection in the laboratory 
As papillomaviruses are difficult to propagate in monolayer cell culture, in vitro studies are 
problematic without the use of other papillomavirus production systems, such as making use 
of pseudovirions (5, 6, 85). HPV pseudovirions (HPV PsVs) are HPV based gene transfer 
vectors, which are mostly indistinguishable from native HPV virions and have been 
successfully used to study HPV antigenicity, receptor usage, entry mechanisms and capsid 
structure (36, 50, 105, 126, 155, 156). They are essentially viral particles which are made up 
of the L1 and L2 structural proteins, forming the ~55 nm capsid encapsulating a reporter 
plasmid, a “pseudogenome” (85, 126, 157). The pseudovirion capsids are structurally similar 
to the native virions, composed of the correct disulphide bonds linking capsomers, due to the 
maturation step during PsV production (section 2.2) (56, 105, 157). This in vitro system is also 
flexible, as no specific packaging sequence is required, and allows high titres of HPV particles 





1.8 Hypothesis  
While much is known about the HPV lifecycle and the virus’ potential to cause cancer (section 
1.4), and preventative measures like vaccines exist and are safe (section 1.2), there is much 
that is inconclusive regarding HPV entry and infection of host cells. Clarifying HPV entry into 
cells could aid in the development of inhibitors, to prevent HPV infection and possible cancer 
development. 
In line with the proposed indirect evidence (52, 105, 106, 128, 158), this study hypothesised 
that furin cleavage of the HPV16 minor capsid protein L2 leads to changes in the quaternary 
capsid structure which can be visualised by high-resolution EM techniques. These changes 
are hypothesised to have consequences for reducing the affinity of HPV16 PsVs for the initial 
cell surface receptor, HSPGs, and allowing virus transfer to the entry receptor or receptor 
complex.   
 
1.9   Aims and Objectives 
Aim 1: To characterise the effects of furin cleavage on HPV16 PsVs through in vitro incubation 
of the viral particles with exogenous furin, high-resolution imaging using transmission electron 
microscopy (TEM) and single particle analysis. 
This aim will be addressed by the following objectives: 
Objective 1.1: To determine whether the addition of exogenous furin can cleave the L2 protein 
within the HPV16 PsV capsid. This will be assessed by SDS-PAGE and silver staining, and 
the results will be compared to furin uncleaved HPV16 PsVs. A cell infection assay will also 
be conducted to confirm the effect of furin cleavage on HPV16 PsV infectivity.  
Objective 1.2: To establish whether furin cleavage of L2 within HPV16 PsVs affects the 
overall capsid morphology, which will be assessed by cryo-electron microscopy and single 
particle analysis of furin cleaved HPV16 PsVs in comparison to uncleaved virions.  
 
Aim 2: To further characterise the effects of furin cleavage on the HPV capsid using computer 
simulated molecular dynamics. 
This aim will be addressed by the following objectives: 
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Objective 2.1: Determine whether any conformational changes seen in the furin cleaved 
HPV16 PsVs affect the ability of the HPV16 PsV to bind to an anionic peptide as a substitute 
for heparin. This will be assessed using molecular dynamics software and generated models 







Unless otherwise stated, chemicals used during this project were of analytical or reagent 
grade. Cell culture media, SDS-PAGE gels and other solutions made up in the laboratory are 
detailed in the Appendix section. Reagents were generally purchased from Merck or Sigma-
Aldrich, unless indicated differently.  
 
2.2 HPV16 PsV production 
2.2.1 Using HPV16 PsVs to study HPV infection 
To study HPV16 infection in vitro, infectious HPV16 pseudovirions (HPV16 PsVs) were 
produced according to established protocols (159-161).  Papillomavirus pseudovirions can 
encapsulate some cellular DNA during production and when making use of human-derived 
virus packaging lines,  such as human embryonic kidney 293TT (HEK293TT) cells, oncogenes 
like the SV40 large and small T antigens present in these cells and resulting pseudovirions 
could be a safety risk (85). Therefore, pseudovirion production was done under biosafety level 
two (BSL-2) conditions. 
HPV16 PsVs are essentially gene transfer vectors and are made of two mammalian 
expression plasmids: pXULL and pCMV GLuc 2 (New England Biolabs) (126, 160). pXULL is 
a codon optimised HPV16 L1 and L2 capsid protein expression plasmid, with an SV40 origin 
of replication (ori). The SV40 ori allows for increased production of the two HPV capsid 
proteins in cells that also express high levels of the SV40 large T antigen, such as HEK293TT 
cells (159, 160). pCMV GLuc 2 is a reporter plasmid representing the HPV pseudo-genome, 
containing a cytomegalovirus immediate early gene promoter (pCMV) and a Gaussia 
luciferase (GLuc) reporter gene, allowing quantification of successful cell infection once the 
reporter plasmid has reached the infected cells’ nucleus. Luciferase activity can be easily 
measured as a read-out for infection. Gaussia luciferase is a ~19 kDa bioluminescent enzyme 
derived from Gaussia princeps and is secreted into the cell culture medium upon successful 
HPV-PsVs infection (159-162).  
Siliconized 1.5 mL and 2 mL Eppendorf tubes were used to prevent loss of HPV16 PsVs, as 
these PsVs may adhere to plastic (162, 163). 
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2.2.2 Cell culture 
HEK293TT cells, the immortalised human keratinocyte cell line HaCaT and the immortalised 
human epithelioid cervical carcinoma cell line HeLa (ATCC® CCL-2™) were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM; Sigma Aldrich), supplemented with 10% Foetal 
Calf Serum (Biochrom) and the antibiotics penicillin (100 U/mL) and streptomycin (100 U/mL) 
(159, 160). Cells were cultured in 10cm cell culture dishes (SPL Life Sciences) and incubated 
in a humidified atmosphere with 5% CO2 at 37°C. All cell lines have been authenticated by 
IDEXX BioAnalytics and all cell culture procedures were done under sterile conditions to 
decrease the risk of contamination. Additionally, mycoplasma testing of cultured cells was 
done routinely, to assess for mycoplasma infection. 
For the antibody neutralisation HaCaT cells were seeded in 12-well plates, at approximately 
5x104 cells per well. The following day, cells were infected with HPV16 PsV-antibody 
complexes (section 2.5.3) (126, 164).  
2.2.3 Plasmid preparation 
pXULL and pCMV-GLuc 2 (New England Biolabs) were amplified in E. coli and grown in 
selection media containing the antibiotics ampicillin (75 µg/mL) for pCMV-GLuc-2 and zeocin 
(50 µg/mL) for pXULL. Plasmids were purified using the PureYield™ Plasmid Maxiprep 
system (Promega).  
2.2.4 Production of HPV16 PsVs 
For HPV16 PsV production, HEK293TT cells were seeded onto thirty 10 cm cell culture dishes 
(Greiner Bio-One) in complete cell culture medium and grown overnight. After this, the calcium 
phosphate transfection method was used to transfect the HEK293TT cells (126, 160). Each 
10 cm cell culture dish was transfected with each of the following plasmids: 5 µg pXULL 
plasmid and 12 µg pCMV-GLuc 2 with 25 µl CaCl2 (final concentration 0.625 M) and 200 µL 
2xHBS buffer (Appendix). After 48 hours, HEK293TT cells were harvested by trypsinisation 
and centrifuged in a 50 mL Falcon tube at 2000 rpm for 2 minutes. The cell pellet was 
resuspended in 5 mL 1xphosphate buffered saline (PBS; Appendix) and centrifuged again. 
The resulting cell pellet was resuspended in 1 mL 1xPBS and transferred to 2 mL siliconized 
Eppendorf tubes. The cell pellet was centrifuged at 3000 rpm for 3 minutes, after which the 
PBS was removed. Then the cell pellet was resuspended in the same volume of PBS, and the 
following was added: 9.5 mM MgCl2, 0.35% Brij®-58 (Polyethylene glycol hexadecyl ether, 
Sigma Aldrich) for solubilizing proteins, 2 µL Benzonase® (Sigma-Aldrich) and 2 µL 
Exonuclease V, to digest un-encapsulated DNA.  
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The cell lysate was incubated at 37°C for 24 hours, with occasional mixing, to allow for HPV16 
PsV inter-L1 disulphide bond formation and capsid maturation (56, 89, 160, 165). After 
pseudovirion maturation, the lysate was chilled on ice for 5 minutes before 0.17 volumes of 5 
M NaCl in 1xPBS was added. This was further chilled on ice for 10 minutes and stored at -
80°C. The lysate then underwent three freeze and thaw cycles at -80°C and 25°C. 
 
2.2.5 Purification of HPV16 PsVs 
Separation of pseudovirion capsids from cell debris and detergent is done by a high salt 
extraction step, followed by ultracentrifugation (56, 160, 161). The cell lysate was centrifuged 
at 8000g for 10 minutes at 4°C, the supernatant was collected in siliconized Eppendorf tubes, 
while the remaining cell pellet was washed with 400 µL High Salt Buffer (HSB) (Appendix) and 
centrifuged at 8000 g for 10 minutes at 4°C. Thereafter, the supernatants were combined, and 
the volume was brought up to 3.5 mL with 1xHSB. 
The cleared cell lysate was then loaded onto a discontinuous caesium chloride (CsCl) gradient 
to further purify the HPV16 PsVs from the cell lysate. This CsCl gradient was prepared as 
follows: 4 mL light CsCl (1.25 g/mL in 1 mL 1xHSB was pipetted into a 13.2 mL Ultra-Clear™ 
centrifuge tube (Beckman Coulter, product #344059). A layer of 4mL heavy CsCl (1.4 g/mL in 
1 mL 1xHSB (Appendix) was gently pipetted under the light CsCl layer and the interface 
between the heavy and light layers was marked on the tube. Finally, the cell lysate was gently 
pipetted onto the light CsCl layer. The sample was centrifuged for 16-17 hours at 20 000 rpm 
at 4°C in a swinging bucket rotor (Beckman SW40Ti). Following ultracentrifugation, the 
centrifuge tubes were removed and clamped with a ring-stand apparatus within a biosafety 
cabinet. HPV16 PsV were then extracted with an 18-gauge needle attached to a 5 mL syringe, 
from the faint band slightly above the CsCl interface. The remaining liquid within the Ultra-
Clear™ centrifuge tube was discarded into a beaker containing Virkon™ (Vetoquinol) 
disinfectant.  
The harvested HPV16 PsV samples were transferred to an Amicon® Ultra-4 filter device with 
100 000 kDa molecular weight cut off (Milipore #UFC810024) and centrifuged at 3 000 rpm 
for 10 minutes. The samples were washed with 3 mL 1xHSB buffer and centrifuged at 3 000 
rpm for 10 minutes again. This was done to remove any remaining CsCl and concentrate the 
HPV16 PsV sample. The HPV16 PsV preparations were then pipetted into siliconized 




2.3 Bicinchoninic assay 
Protein concentration of each HPV16 PsVs preparation was measured using the Pierce™ 
BCA Protein Assay Kit (Thermo Scientific), according to the manufacturer’s instructions. 
 
2.4 Furin cleavage of HPV16 PsVs 
Furin cleavage of HPV16 PsVs was performed according to Schäfer et al. (126). Briefly, 
purified HPV16 PsVs (~0.35 mg/mL) were incubated with furin (1.8 U/µg; New England 
Biosystems) in siliconized Eppendorf tubes at 37°C for 14 hrs (126). Successful furin cleavage 
was assessed by SDS-PAGE (section 2.5.1) followed by silver staining (section 2.5.2) and 
further supported by a cell culture infection assay (section 2.5.4). 
 
2.5 Assessment of HPV16 pseudovirion preparation quality 
2.5.1 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis  
Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) is used to 
separate proteins based on their molecular weights and is used as an assessment for protein 
purity and a qualitative check on the amount of protein present within a sample. Therefore, 
this technique was used to assess purity of HPV16 PsV preparations as conducted previously 
(47, 126). 
SDS-PAGE gels consisted of 3% stacking gel and either 7.5% or 10% separating gel 
(Appendix) as indicated. 5X Pierce™ Lane Marker Reducing Sample Buffer (Thermo 
Scientific) containing Dithiotreitol (DTT) was added to experimental HPV16 PsV samples (0.1 
µg/µL) which were heated at 95°C for 10 minutes, for protein denaturation. The denatured 
pseudovirion samples were then loaded onto the set SDS-PAGE gels and protein samples 
were electrophoresed in 1X running buffer (Appendix), according to established protocols (47, 
126). A protein molecular weight marker, Colour Pre-stained Protein Standard, Broad Range 
Marker (11-245 kDa; New England Biolabs) was used to estimate loaded protein sample 
molecular weights. Electrophoresed gels were stained for protein visualisation and 
assessment (section 2.5.2). 
 
2.5.2 Pierce™ silver staining 
SDS-PAGE gels were stained to visualise the HPV16 PsV L1 and L2 proteins (and any 
possible contaminants) using the Pierce™ silver stain kit (Thermo Scientific), according to 
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the manufacturer’s instructions. Briefly, SDS-PAGE gels were washed twice for 5 minutes in 
ultrapure dH2O. Gels were then fixed twice for 15 minutes each, using a 30% ethanol:10% 
acetic acid solution. Afterwards, the  gels were washed twice for 5 minutes each with 10% 
ethanol, followed by two washes in ultrapure dH2O. Gels were then sensitized for 1 minute 
with sensitiser solution made according to the protocol (Pierce™ silver stain kit; Appendix), 
followed by two 1 minute washes in ultrapure dH2O. Gel staining was done for 30 minutes 
using the staining solution (Pierce silver stain kit; Appendix), followed by two quick 20 second 
washes with ultrapure dH2O. Thereafter, gels were developed for 2 to 3 minutes development 
using the developer working solution (Pierce silver stain kit; Appendix) until protein bands 
appear. The developing reaction was then stopped with 10% acetic acid for 10 minutes. An 
HPV16 PsV L2 protein band was expected at 75 kDa and a prominent HPV16 PsV L1 protein 
band was expected to co-migrate at 55 kDa in pure HPV16 PsV preparations (47, 112). 
2.5.3 Antibody neutralisation of HPV16 PsVs 
To assess quality and infectivity of the pseudovirion preparations, HPV16 PsVs were pre-
incubated with either the HPV16 neutralising antibody (H16.V5; kindly provided by Neil D. 
Christensen, Pennsylvania State University College of Medicine, USA) or the HPV18 
neutralising antibody (HPV18.J4; kindly provided by Neil D. Christensen, Pennsylvania State 
University College of Medicine, USA) at a final concentration of 1:1000 for 1 hour at 4°C (126, 
159, 164). HaCaT cells were seeded according to Schafer et al. (126, 164) in 75 cm2 cell 
culture flasks (SPL Life Sciences). These antibody-complexed HPV16 PsVs were then added 
to HaCaT cells and resulting luciferase secretion by infected cells was measured as a read-
out for HPV infection (section 2.5.3). H16.V5 was expected to neutralise (i.e. abolish) infection 
of HPV16 PsVs, thereby acting as a positive control, while the HPV18 antibody acted as a 
negative control, and was not expected to affect HPV16 PsV infection of HaCaT cells.  
2.5.4 Cell infection assay with furin cleaved HPV16 PsVs 
To assess the infectivity of HPV16 PsV preparations, cell infection assays were conducted 
using HeLa cells, which were seeded in monolayer culture as described (section 2.2.2) (126). 
Furin cleaved or furin uncleaved HPV16 PsVs were added to cultured HeLa cells and 
luciferase secretion into the cell supernatant was measured 48 hours later (section 2.5.5). 
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2.5.5 Luciferase assay  
Luciferase assays were performed to quantify the infectivity of HPV16 PsV preparations in 
HeLa and HaCaT cells, where the infection was measured 48 hours after infection. 5 μL cell 
supernatant was added to a white 96-well plate (Nunc) and luciferase activity was measured 
using the Gaussia luciferase (GLuc) Assay Kit (New England Biolabs) together with a 
GloMax® Explorer Multimode Microplate Reader (Promega). Per sample, freshly prepared 
GLuc Assay Solution made up of 0.5 μL BioLux GLuc Substrate with 50 μL BioLux Assay 
Buffer (New England Biolabs) was added per well. Luciferase luminescence was measured 
with 2 seconds lag time over 10 seconds integration time. 
 
2.6 Increasing the concentration of furin cleaved HPV16 PsVs 
For imaging by cryo-electron microscopy, furin cleaved HPV16 PsVs were further 
concentrated. A small steel rod (61.57 mm3 ) was added to the bottom of an Amicon® Ultra-4 
filter device with 100 000 kDa molecular weight cut off (Milipore #UFC810024) to minimise the 
loss of HPV16 PsVs within the filter. 38 µL of the furin cleaved HPV16 PsV preparation (~0.35 
mg/mL) was added to the filter, followed by 250 µL 1xHSB. This was then centrifuged at 
14 000x g at 4°C in a benchtop centrifuge for 20 minutes. 250 µL 1xHSB was added and the 
centrifugation step was repeated twice more, followed by three rounds of 15 minute 
centrifugation steps. In each case, 250 µL 1xHSB was added. The bottom of the Amicon® 
filter was emptied and the sample was spun for another 15 minutes without adding HSB. 
Finally, 13 µL HSB was added to the concentrated HPV16 PsV, making the concentration ~0.6 
mg/mL, before transferring the sample to a siliconized Eppendorf tube and preparation of the 
cryo-electron microscopy (cryo-EM) grids (section 2.10). 
 
2.7 Negative stain Electron Microscopy  
Negative stain transmission electron microscopy (TEM) was used to visualise HPV16 PsVs, 
to assess the overall structure, dispersion, and homogeneity of the preparations.  
 
2.7.1 Grid preparation 
Carbon coated copper grids (Electron Microscopy Sciences) were glow-discharged in air at a 
plasma current of 25 mA for 30 seconds using an EMS100× Glow Discharge Unit (Electron 
Microscopy Sciences) to render the grids more hydrophilic and negatively charged. 2.5 µL of 
HPV16 PsV preparation was pipetted onto the glow-discharged grid and allowed to adhere for 
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30 seconds. The excess sample was then gently and indirectly blotted off each grid with filter 
paper. Each grid was then washed with 3 drops of distilled water (dH2O) followed by staining 
with 2 drops of 2% aqueous uranyl acetate (SPI supplies), indirectly blotting the grid dry with 
filter paper wedges between each step. Each grid was then air dried before transmission 
electron microscopy (TEM). 
For the furin uncleaved HPV16 PsVs, processing by furin and increasing the concentration of 
the virions was not done (section 2.6). The furin unprocessed HPV16 PsVs (~0.4 mg/mL) were 
directly added to the prepared grids after production and storage at -80°C (section 2.10). 
 
2.7.2 Transmission electron microscopy 
Each negative stain grid was loaded, using a single side-entry grid holder (Gatan),  onto a 
Tecnai T20 Transmission Electron Microscope (FEI) with an LaB6 electron gun operating at 
200kV, and equipped with a CCD camera (2048 x 2048-pixel; Gatan). Micrographs were 
collected at SA 53 000 x magnification in low dose mode. 
 
2.8 Cryo-EM grid preparation for F20 TEM 
Quantifoil® ‘holey’ R2/2 carbon coated copper grids were glow-discharged in air at a plasma 
current of 25 mA for 30 seconds using an EMS100× Glow Discharge Unit (Electron Microscopy 
Sciences) to render the grid more hydrophilic and negatively charged. The concentration of 
HPV16 PsVs (~0.5 mg/mL) was sub-optimal for cryo-EM, therefore carbon coated cryo-EM 
grids were used to increase particle adsorption to the grid and the number of particles available 
for imaging.  A Vitrobot Mark IV (Thermo Scientific) was used to apply, blot, and vitrify each 
sample. 3 µL of HPV16 PsV was pipetted onto glow discharged grids and allowed to adhere 
in a 100% humidified chamber for 30 seconds, before being blotted with filter paper and 
plunged into a bath of liquid ethane, cooled by liquid nitrogen. The vitrified grid was then 
transferred into a labelled grid box and this was placed inside a 50 mL Falcon. 
 
2.9 Transmission electron microscopy and data collection 
The vitrified cryo-EM grid was loaded onto the single grid side-entry cryo-holder (Gatan) under 
liquid nitrogen. The specimen holder was then inserted into the Tecnai F20 microscope 
(Phillips/FEI) and allowed to equilibrate to about -180°C for 90 minutes before data collection. 
Micrographs were collected using the parameters listed in Table 3.2. 
36 
 
2.9.1 Micrograph pre-processing 
The micrographs were stored locally for processing on a computer with 128Gb RAM and four 
1070 Nvidia GPUs. These micrographs were imported into REgularised Likelihood 
OptimisatioN (RELION) 2.1 software for three-dimensional reconstruction (166-170). Contrast 
transfer function (CTF) estimation was performed using Gctf software, with dose-weighting 
(171). Particles within the micrographs were manually picked from micrographs, and 
normalised. Then, the contrast was inverted, and the particles were extracted in a box size of 
600 pixels without rescaling. 
  
2.9.2 Three-dimensional reconstruction 
Two-dimensional (2D) class averages of the extracted particles were calculated which are 
compiled of several aligned particles with similar features for a particle projection or orientation 
(172). The particles were averaged into ten 2D classes in twenty iterations, with a 
regularisation parameter T = 2.  2D classes had a mask diameter of 600 Å and the images 
were aligned. There was an in-plane angular sampling of 6° with an offset search range of 5 
pixels and an offset search step of 1 pixel. The pooled particles were pre-read into RAM with 
four GPUs used, split over four MPI processes and two threads. A subset of classes was 
selected from the 2D class averages generated after re-centering. These classes were 
selected as they represented particles with the highest resolution in the data collected and 
underwent three-dimensional (3D) classification. The 3D classification was done on the 
selected 2D classes, with a featureless sphere generated in the software System 
for Processing Image Data from Electron microscopy and Related fields (SPIDER) as the 
reference map, which was lowpass filtered to 60 Å (173).  Icosahedral (I2) symmetry and 
regularisation parameter T = 4 was applied. The mask diameter was 600 Å with an angular 
sampling interval of 3.7°, an offset search range of 5 pixels and an offset search step of 1 
pixel. Resulting 3D classes were visualised using UCSF Chimera (‘Chimera’) for analysis 
(174). The 3D classes with the highest resolution were selected and used for 3D refinement. 
The best 3D class was used at 60 Å lowpass filtered reference map and icosahedral (I2) 
symmetry was applied. Initial angular sampling was 7.5° as HPV is an icosahedral virus, with 
a local search from auto sampling 1.8°, initial offset search range of 5 pixels and an offset 
search step of 1 pixel, which would be increased as the 25 iterations proceeded. The resulting 
3D refinement model was assessed using UCSF Chimera (section 2.14) and the Fourier Shell 
Correlation (FSC) curve.  
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2.10  Cryo-EM grid preparation for high resolution imaging 
Quantifoil® ‘Holey’ R2/2 carbon-coated copper grids (Electron Microscopy Sciences) were 
used for both the furin cleaved and furin uncleaved HPV16 PsV samples. An additional thin 
layer of carbon was deposited onto the holes within the copper grids for the furin cleaved 
HPV16 PsV samples. This was not done for the furin uncleaved HPV16 PsV samples. ‘Holey’ 
R2/2 carbon coated copper grids (Quantifoil) were covered with an additional layer of thin 
amorphous carbon before being glow-discharged in air at a plasma current of 25 mA for 30 
seconds using a EMS100× Glow Discharge Unit (Electron Microscopy Sciences, USA) to 
render the grid more hydrophilic and negatively charged.  
Sample application to cryo-EM grids and vitrification was done using a Vitrobot (Thermo 
Scientific). The concentration of HPV16 PsVs (~0.6 mg/mL) was sub-optimal for cryo-EM, 
therefore carbon-coated cryo-EM grids were used to increase particle adsorption to the grid 
and the number of particles available for imaging. 2.5 µL of the HPV16 PSV preparations was 
pipetted onto the glow discharged thin carbon coated ‘Holey’ R2/2 carbon grids (Quantifoil) 
within the 100% humified chamber of the Vitrobot set at 4°C and allowed to adhere for 5 
minutes. Subsequently, the excess sample was blotted away from both sides of the grid, for 
30 seconds using the Vitrobot. The grid was then plunged into a bath of liquid ethane, cooled 
by liquid nitrogen, before being transferred to a labelled grid box under liquid nitrogen for 
storage. The grid boxes were then stored under liquid nitrogen within 50mL Falcon tubes, 
before being shipped to the Electronic Bio-imaging Centre (eBIC) at Diamond Light Source 
(UK). 
 
2.11  High resolution transmission electron microscopy of HPV16 
PsVs  
The furin cleaved and uncleaved datasets were collected on G3 Titan Krios cryo-electron 
microscopes (Thermo Fisher Scientific), operating at 300kV with an X-FEG electron source 
(Schottky) at eBIC (Diamond Light Source, UK) equipped with either a K2 detector (Gatan; 
furin cleaved dataset) or a K3 detector (Gatan; furin uncleaved dataset) in counting mode with 
data acquisition using EPU software. Acquisition parameters are listed in Table 3.2 and Table 
3.3. Each dataset was collected over several grid squares within a single cryo-EM grid, without 
major changes to microscope parameters, allowing the multi-frame movies collected to be 
combined into a single dataset. 
Movies were collected in low-dose mode at a range of defocus values, to fill in the zeros of 
the contrast transfer function (CTF) although the defocus values were close to focus, to retain 
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as much high-resolution information as possible (172). The HPV16 PsV is a large and 
spherical proteinaceous virion, making it easily identifiable even close to focus, therefore it 
was unnecessary to use large defocus values (48, 172). Gain correction was done on both 




2.12  Single particle analysis of furin uncleaved HPV16 PsVs 
2.12.1  Movie pre-processing 
All processing was done in the RELION 3.1 pipeline with wrappers to the relevant programs 
(MotionCor2, ctffind4), unless otherwise indicated (168, 170, 171, 175). The micrographs were 
transferred from Diamond Light Source to the local laboratory and stored locally, for 
processing. A summary of the single particle analysis for the furin uncleaved HPV16 PsVs  is 








Figure 2.1, Single particle analysis of furin uncleaved HPV16 PsVs using RELION. Multi-frame 
movies were motion corrected using MotionCor2, and CTF parameters were estimated for each 
micrograph using Ctffind4. Individual HPV16 PsVs were extracted from the data using manually 
selected particle co-ordinates and subjected to three rounds of two-dimensional classification. After 
each round the best classes were chosen and the final particle set was used to generate a three-
dimensional model which then underwent three-dimensional refinement. A solvent mask was then 
generated from this model with the interior map density deleted in UCSF Chimera. The particles were 
then subjected to three-dimensional classification followed by selection of the best class.  Subsequently, 
the particles underwent three dimensional refinement and per particle defocus values were estimated 




Multi-frame movies of the furin uncleaved HPV16 PsV dataset were imported into the RELION 
3.1 pipeline and MotionCor2 was used to correct for beam-induced motion during data 
collection (175), the micrographs were binned by a factor of 2, leading to scaling of 1.06 
Å.pixel-1 as these movies were taken in “super-resolution” mode on a K3 detector (Gatan) with 
a pixel size of 0.53 Å/pix for 9 464 movies. Contrast Transfer Function (CTF) parameters were 
estimated using ctffind4 (176). CTF curves (with phase and amplitude terms) for corrected 
micrographs were assessed for fit to the theoretical CTF and micrographs with sub-optimal 
fits to the theoretical CTF were discarded, leaving 9 050 selected micrographs for further 
processing. Particle co-ordinates within micrographs were selected manually using RELION, 
producing a total of 20 595 particles from 8 862 micrographs. Particles were normalised, the 
contrast was inverted, and particles were extracted from micrographs in a box size of 750 
pixels at a sampling of 1.06 Å. pixel-1, with no downscaling. A small particle box size was used 
to minimise computational costs of downstream processing while retaining as much high-
resolution data as possible. 
 
2.12.2 Three-dimensional reconstruction of furin uncleaved HPV16 PsVs 
2D class averages of the extracted particles were calculated to classify the extracted particles 
into 2D class averages based on projection image matching (170). Three successive rounds 
of reference free 2D classification were done to classify the extracted particles into fifty 2D 
class averages in twenty-five iterations, with a regularisation parameter T=2 and a solvent 
mask diameter of 800 Å. Particle images were aligned and an in plane angular sampling of 5 
pixels, and offset search range of 5 pixels and an offset search step of 1 pixel was applied. 
After each round of 2D classification, the highest resolution class averages were selected, 
eliminating sub-optimal particles and random noise from the dataset. The particles from each 
class were also “regrouped” into ~ 200 classes in each 2D classification step, to improve 
estimates of their average noise power spectrum. This process resulted in 4 216 particles in 
142 groups. Then, the particles were subjected to 3D classification with a previously generated 
furin uncleaved model as a reference map. The reference map was lowpass filtered to 60 Å, 
with no symmetry (C1) for 3D classification of the data into 4 classes. A regularisation 
parameter T = 4 was also applied to the twenty-five iterations, with a mask diameter of 700 Å. 
The particles producing the highest resolution 3D class average were selected, resulting in 3 




An initial model was generated from the selected particles using RELION and the Stochastic 
Gradient Algorithm (SGD), with no symmetry (C1) applied (168, 177). A mask diameter of 700 
Å was applied, with an initial angular sampling of 15°, an offset search range of 6 pixels, and 
offset search step of 2 pixels. The resulting model was 15 Å and was used as a reference map 
for an initial 3D refinement. The initial model was lowpass filtered to 60 Å, and icosahedral 
symmetry was applied (I2). A small 700 Å mask was applied and an initial angular sampling 
of 3.7 °, with a local search from auto sampling of 0.9°, as this was a large icosahedral virus. 
The initial offset range and initial offset step was 5 and 1 pixel(s) respectively. This resulted in 
a final resolution of 8.03 Å. The initial 3D refinement was lowpass filtered to 20 Å using 
relion_image_handler and was opened in the program UCSF Chimera. The map was 
segmented into regions and the density corresponding to genetic material inside the capsid 
was deleted, leaving a ‘capsid-only’ map (56). This map was saved and used in RELION to 
generate a solvent mask for downstream refinement. This solvent mask was lowpass filtered 
to 20 Å generated with an initial binarization threshold of 0.00103, the binary map was 
extended by twenty pixels and a soft edge of ten pixels was added. Postprocessing was done 
on the refined HPV16 PsV map, with the ‘capsid-only’ solvent mask. The post-processed map 
was sharpened with a user provided β factor of -20 and an ad-hoc lowpass filter of 8 Å. Per 
particle defocus values for the dataset were estimated. To further improve resolution, the data 
was subjected to a final 3D refinement and postprocessing as previously, with the ‘capsid-
only’  solvent mask. The 3D refined map was sharpened with a user-provided β factor of -20 
and an ad-hoc lowpass filter of 8 Å. This led to a final 3D reconstruction of the furin uncleaved 
HPV16 PsV at 7.29 Å, according to the “gold standard” FSC curve (167, 170, 178). 
 
2.13  Single particle analysis of furin cleaved HPV16 PsVs 
2.13.1  Movie pre-processing 
All processing was done in the RELION 3.1 pipeline with wrappers to the relevant programs 
(MotionCor2, ctffind4), unless otherwise indicated (168, 170, 175, 176). The micrographs were 
transferred from Diamond Light Source to the local laboratory and stored for processing. A 
summary of the single particle analysis leading to a 3D reconstruction is presented in Figure 




Figure 2.2. Single particle analysis of furin cleaved HPV16 PsVs using RELION. Multi-frame 
movies were motion corrected using MotionCor2, and CTF parameters were estimated for each 
micrograph using Ctffind4. Individual HPV16 PsVs were extracted from the data using manually 
selected particle co-ordinates and subjected to three rounds of two dimensional classification. After 
each round the best classes were chosen and the final particle set was used to generate a three 
dimensional model which then underwent three dimensional refinement. A solvent mask was then 
generated from this model with the interior map density deleted in UCSF Chimera. The particles were 
then subjected to two rounds of three dimensional classification with selection of the best classes after 
each round.  Subsequently, the particles underwent three dimensional refinement and per particle 
defocus values were estimated during CTF refinement. Finally, the model was postprocessed with a β 





Micrographs of the furin cleaved HPV16 PsV dataset were imported into the RELION pipeline, 
as the multi-frame movies had already been motion-corrected using MotionCor2, to correct for 
beam induced motion during data collection (175). These micrographs had a pixel size of 
1.048 Å.pixel-1, and data parameters in Table 3.3 were input into RELION. Contrast Transfer 
Function (CTF) parameters were estimated using ctffind4 (176). CTF curves (with phase and 
amplitude terms) for corrected micrographs were assessed for fit to the theoretical CTF and 
micrographs with sub-optimal fits to the theoretical CTF were discarded, leaving 3 774 
selected micrographs for further processing. Particle co-ordinates within micrographs were 
selected automatically using RELION, and the resulting co-ordinates were curated manually, 
leaving a total of 20 549 particles from 3 551 micrographs. Particles were normalised, the 
contrast was inverted, and particle coordinates were extracted from micrographs in a box size 
of 750 pixels at a sampling of 1.048 Å.pixel-1, with no downscaling.  
 
2.13.2 Three-dimensional reconstruction 
Three successive rounds of reference-free 2D classification were done to classify the 
extracted particles into 2D class averages based on projection image matching (170). After 
each round of 2D classification, the highest resolution class averages were selected, 
eliminating sub-optimal particles and random noise from the dataset. The particles from each 
class were also “regrouped” into ~ 500 classes in each 2D classification step, to improve 
estimates of their average noise power spectrum. This process resulted in 8 067 particles in 
309 groups. Using RELION and the Stochastic Gradient Descent algorithm an initial model 
was generated from the selected particles, with icosahedral (I1) symmetry (168, 177). A mask 
diameter of 700 Å was applied, with an initial angular sampling of 15°, an offset search range 
of 6 pixels, and offset search step of 2 pixels. The resulting model was 15 Å and was used as 
a reference map for an initial 3D refinement. This high-resolution 3D refinement is an 
automated procedure, which calculates the Fourier Shell Correlation (FSC) for accurate 
determination of resolutions without over-fitting the data (168, 170). The 15 Å initial model was 
lowpass filtered to 60 Å, and no symmetry was applied (C1 symmetry). A 700 Å mask was 
applied and an initial angular sampling of 3.7°, with a local search from auto sampling of 0.9°, 
as this was a large icosahedral virus. The initial offset range and initial offset step was 5 and 
1 pixel(s) respectively. This resulted in a model with a final resolution of 10.34 Å. 
The initial 3D refinement was lowpass filtered to 20 Å using relion_image_handler and was 
opened in Chimera. The map was segmented into regions and the density corresponding to 
interior density inside the capsid was deleted, as this unordered region may affect the overall 
resolution of the finalised map, leaving a “capsid-only” map (56). This map was saved and 
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used in RELION to generate a solvent mask for downstream refinement. The solvent mask 
was lowpass filtered to 30 Å generated with an initial binarization threshold of 0.0044, the 
binary map was extended by five pixels and a soft edge of ten pixels was added. The map 
was also flipped 90° along the Z-axis of UCSF Chimera, to align with the data in RELION. The 
10.34 Å map was lowpass filtered to 60 Å, and used a reference map, with no symmetry (C1) 
for 3D classification of the data into 4 classes. A regularisation parameter T = 4 was also 
applied to the twenty-five iterations, with a mask diameter of 750 Å. The particles producing 
the highest resolution 3D class average were selected, resulting in 8 067 particles grouped 
into 604 groups. A second 3D classification was done on these selected particles as 
previously, and the highest resolution 3D class averages were again selected, and 7 187 
particles subjected to 3D refinement. 3D refinement was performed on the data, with a 
previously generated high-resolution HPV16 PsV map as the reference map, with the “capsid-
only” solvent mask. The reference map was lowpass filtered to 30 Å and icosahedral (I2) 
symmetry, initial angular sampling of 3.7°, with a local search from auto sampling of 0.9° was 
applied. The initial offset range and initial offset step was again 5 and 1 pixel(s) respectively, 
leading to a reconstruction at 6.09 Å. Postprocessing was done on the refined HPV16 PsV 
map, with the “capsid-only” solvent mask generated. The post-processed map was sharpened 
with a user-provided β factor of -95 and an ad hoc lowpass filter of 5 Å. Afterwards, per-particle 
defocus values for the dataset were estimated. To further improve resolution, and the data 
was subjected to a final 3D refinement as in the previous refinement, and post-processing, 
with the “capsid-only” solvent mask. This led to a final 3D reconstruction of the furin cleaved 
HPV16 PsV at 5.006 Å, according to the “gold standard” FSC curve (section 2.14). 
 
2.14  Resolution determination 
The “gold standard” Fourier Shell Correlation (FSC) was used for automated resolution 
determination within RELION. When an FSC curve drops below 0.143, this is a good indicator 
of overall map resolution (178, 179). During 3D refinement particles are split into random 
halves and two 3D reconstructions are generated, which are independent of each other, to 
prevent ‘over-fitting’ of random noise in the data. This process also estimates the accuracy of 
angular assignments, allowing RELION to automatically determine when the 3D refinement 
has converged from the two half-reconstructions (168, 170). Comparison of each 





2.15  Structure comparison 
An independent and published HPV16 L1-only capsid asymmetric unit was retrieved from the 
Protein Data Bank (PDB ID: 5kep) and used as a model to confirm the handedness of the 
HPV16 PsV reconstructions produced here (50). UCSF Chimera (‘Chimera’) was used to view 
each HPV16 PsV reconstruction generated and to dock 72 copies (one for each HPV16 
pentamer) of the L1 pentamer (part of the PDB 5kep structure) into the PsV reconstruction 
using the ‘fitmap’ command within Chimera, to optimise docking within the reconstruction 
(174). 
Similarly, a high-resolution cryo-EM structure of an HPV16 quasivirion (EMB-6620) was 
retrieved from the Electron Microscopy Data Bank (EMDB) and docked into the 
reconstructions generated here, using Chimera, providing a qualitative measure of resolution 
obtained (50). As this quasivirion reconstruction was produced differently to our pseudovirion 
reconstructions, this structure was not used for evaluation of the effects of furin cleavage on 
the HPV capsid.  
 
2.16  Assessment of HPV16 PsV conformation changes 
The final furin cleaved (5 Å) and uncleaved (7.29 Å) HPV16 PsV reconstructions were 
assessed for any changes in conformation, which may be attributed to furin cleavage of L2. 
To achieve this, both models with the published cryo-EM structure of HPV16 (EMD-6620) 
were imported into Chimera. The two reconstructions generated in this project were docked 
into the published EMD-6620 map, using the ‘fitmap’ command in Chimera.  
To generate atomic-level structures of our furin cleaved and uncleaved HPV16 reconstructions 
a published PDB of the L1-only capsid asymmetric unit was fitted into the two density maps. 
Each L1 chain within the HPV16 asymmetric unit (PDB ID: 5kep) was docked individually into 
either the furin cleaved or uncleaved HPV16 PsV reconstructions using ‘fitmap’ command in 
Chimera, known as rigid-body docking. Following this, the docked L1 chains of each 
reconstruction were combined into a single PDB, resulting in two PDB L1 models with each 
L1 subunit in either the furin cleaved or uncleaved conformation. The command matchmaker 





Figure 1.2[C]). Chain A was not aligned using ‘matchmaker’ in Figure 3.6 as this figure 
demonstrates that both hexavalent and pentavalent capsomeres move after furin cleavage of 
L2. The root mean squared deviation (RMSD) was used as a quantitative measure of 
differences between the generated furin cleaved and uncleaved structures, after alignment of 
chain A. RMSD was calculated by comparing all amino acids in each docked L1 chain (chain 
A to F) between the furin cleaved and uncleaved HPV16 PsV.  
The distance that the L1 chains moved after furin cleavage of L2 around the canyon between 
hexavalent and pentavalent capsomere (the putative heparin-binding site) was measured in 
Chimera using the ‘distances tool’. Atoms within the L1 chains forming the asymmetric unit 
generated above were selected and the difference between the atom in the furin uncleaved 
versus the furin cleaved conformation was measured in angstroms (Å).  
 
2.17  Molecular dynamics 
Molecular dynamics was used to determine whether the change in capsid conformation 
observed between the furin cleaved and uncleaved HPV16 PsV reconstructions had any 
functional relevance for HPV16 attachment to heparin, a widely used substitute for HSPGs, 
the initial HPV cell attachment receptor (section 1.5). 
After retrieving the two cryo-EM density maps from the EMDB a published structure of HPV16 
(EMD-6620) was subtracted from the associated HPV16 with heparin bound structure (EMD-
6619)  using the ‘vop subtract’ command in Chimera, to generate a map containing heparin 
density, representing the putative HSPG binding site on the HPV16 capsid.  This heparin 
density was lowpass filtered using to 8 Å using relion_image_handler (50, 167, 169, 170). An 
aspartic acid peptide was generated to simulate the length and negative charge of heparin, 
given the difficulties in generating molecular dynamics force fields for these highly 
heterogenous and flexible models. The peptide was generated in Chimera using the ‘Build 
Structure’ menu and is composed of eighteen repeating residues of aspartic acid, with 
alternating Φ = -57° and ψ = -47° for an α helix, or Φ = -139° and ψ = -135° for an anti-parallel 
β sheet, to generate a linear amino acid peptide. This peptide was rigid body docked into the 
heparin density map using the ‘fitmap’ command in Chimera. Following this, the aspartic acid 
peptide was combined with the three L1 chains (chains A, B and F) around the heparin density 
in either the furin cleaved or uncleaved conformation (section 2.16), using ‘copy/combine’ 
option in Chimera. This was done to generate two models; each composed of three HPV16 
L1 chains, either in the furin cleaved or uncleaved conformation, with an aspartic acid peptide, 
to represent heparin, in the putative heparin location on the HPV16 capsid. 
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Finally, these models were imported into ChimeraX and a real-time molecular dynamics 
simulation was done using ISOLDE for both the furin cleaved and uncleaved HPV16 PsV 
models (180, 181). Hydrogens were added to the models and the simulation was run at 310 
Kelvin overnight. The results were assessed manually and hydrogen bonds were measured 
between interacting amino acids on each L1 chain and the aspartic acid peptide, using the 
‘find H bond’ option within ChimeraX, according to parameters specified in (182) and coloured 
black. The hydrogen bonding constraints were relaxed by 0.4 Å and 20°, and these hydrogen 
bonds were coloured orange. 
 
2.18  Investigating the density maps for the location of L2  
We investigated the location of the L2 protein within both the furin uncleaved and furin cleaved 
HPV16 PsV density maps, and whether after furin cleavage of L2, there was a re-arrangement 
of the L2 protein within the HPV16 PsV capsid. The atomic resolution structure of the HPV16 
L1 only asymmetric unit (PDB ID: 5kep) (Figure 1.1[C]) was used to generate an L1-only 
density map in Chimera. To achieve this, icosahedral symmetry was applied using the ‘sym’ 
command in Chimera, generating sixty copies of the L1-only asymmetric unit, forming an entire 
HPV16 capsid. Following this, the command ‘molmap’ was used to generate a 3D density map 
of only the L1 protein at 5 Å and 7.3 Å respectively. Then the two HPV16 PsV density maps 
generated in this project were imported, furin cleaved map was fitted into the 5 Å L1 only 
density map, while the furin uncleaved map was fitted into the 7.3 Å map. The command ‘vop 
subtract’ was used to subtract either the furin uncleaved or furin cleaved HPV16 PsV map 
from the 7.3 Å or 5 Å L1-only map respectively. The remaining density should only correspond 





Investigation into the entry mechanisms used by HPV for infection of host cells may aid in the 
development of new approaches to prevent infection and decrease the risk of HPV linked 
cancers. After HPV attaches to cell surface HSPGs, a host protease (furin) cleaves the minor 
HPV capsid protein, L2. Furin cleavage of L2 is a necessary step in HPV infection, without 
which the virus is far less infectious (sections 1.5.2 and 1.5.3) (106, 110, 116, 118). Therefore, 
detailed investigation of the effects of furin cleavage on the HPV capsid may present new 
avenues for therapeutic development. Furthermore, it has been proposed in the literature that 
changes to the HPV capsid structure after furin cleavage prime the virus for entry into host 
cells, although this has never been directly visualised. This may be achieved by reducing the 
virus’s affinity to HSPGs, or a structurally similar substitute molecule, heparin, allowing virus 
transfer to the entry receptor(s) (section 1.5.3). This work made use of HPV16 PsVs as they 
are functionally and morphologically similar to native HPV16 and have been successfully 
studied using structural biology (41, 49, 50, 102, 105). HPV16 PsVs were used to directly 
visualise structural changes to the HPV16 PsV capsid upon furin cleavage and the associated 
consequences for HPV binding to heparin. 
 
3.1 HPV16 PsV production and evaluation 
Before use in in vitro and resulting computational analysis, the purity and infectivity of the 
HPV16 PsVs were evaluated. Denaturing SDS-PAGE followed by silver staining revealed 
uncontaminated HPV16 PsV preparations and a prominent L1 protein band at 55 kDa 
associated with a co-migrating L2 protein band at 75 kDa in pure preparations of the HPV16 
PsVs (Figure 3.1[A]). HPV16 PsV infection of HaCaT cells, after virus pre-incubation with 
either the HPV16 specific antibody (H16.V5) or the HPV18 specific antibody (H18.J4; negative 
control) (section 2.5.3) revealed complete abolishment of infection using HPV16 PsV bound 
with H16.V5 antibody, but no decrease in infection using HPV16 PsVs pre-incubated with 
H18.J4 (Figure 3.1[B]). Finally, negative staining and TEM visualisation (section 2.7) of purified 









Figure 3.1. HPV16 PsVs are uncontaminated and display spherical capsids. [A] Silver stained 
SDS-PAGE gel showing purity of HPV16 PsVs preparation. A thick protein band corresponding to the 
L1 protein (55 kDa) and a thin L2 band (75 kDa) of HPV16 were seen in the preparations used in this 
project. [B] HPV16 PsVs (encapsidating a Gaussia luciferase reporter gene) were pre-incubated in the 
presence or absence of an HPV16 (H16.V5) or an HPV18 (H18.J4) neutralising antibody and added to 
HaCaT cells. Luciferase values are presented as x-fold change relative to HPV16 PsV infection of 
HaCaT cell in the absence of any antibodies, which was set to 1. Bars depict mean values, while error 
bars indicate standard error of the mean. [C] Negative stain and transmission electron microscopy of 




3.2 The structure of HPV16 PsVs 
After determining that the HPV PsV preparations were uncontaminated and infectious, the 
particles were vitrified onto holey thin-carbon coated copper grids and imaged by cryo-EM 
(section 2.9 and Table 3.1). Cryo-EM was done to confirm whether the HPV16 capsid can be 
successfully imaged by cryo-electron microscopy and lead to a 3D reconstruction, before 
further investigation. The HPV16 PsVs were ~55 nm size, homogenous and well distributed 
within the holes of the cryo-EM grid (Figure 3.2[A]). The collected dataset resulted in a 3D 
reconstruction at 34 Å resolution, which displayed the ~55 nm spherical diameter and “knobby” 
spherical capsid exterior, made up of 72 capsomeres with icosahedral symmetry (Figure 3.2[B] 
and Table 3.1). These capsomeres appeared pentameric, as would be expected if each 
capsomere was composed of five L1 proteins. This is confirmed by ‘rigid-body’ docking of a 
PDB made up of the L1 capsid protein (PDB ID: 5kep) structure into our cryo-EM map (section 
2.15) (50). The Fourier Shell Correlation (FSC) curve demonstrated the achieved resolution 
at 34 Å, where the curve crosses the FSC threshold of 0.143, the ‘gold- standard’ for 
determining density map resolution (Figure 3.2[C]) (178, 179). These results demonstrate the 




Table 3.1. Cryo-EM data collection parameters and refinement statistics for the low-resolution 
furin uncleaved HPV16 PsV dataset. 
Data collection parameters 
Microscope F20 
Detector US 4000 CCD camera (Gatan) 
Voltage (kV) 200 
Pixel size (Å) 2.11 
Nominal magnification 53 000 
Defocus (µm) -0.3 
Number of images collected 77 
Microscope parameters 
Cs (mm) 1.22 
Map reconstruction 
Initial particle number  755 
Final particle number 681 
Particle box size (pixel) 600 
Resolution (gold standard FSC = 0.143) (Å) 34 
Map sharpening β factor (Å2) 0 

















Figure 3.2. Cryo-electron microscopy (cryo-EM) of HPV16 PsVs confirm structure of the HPV16 
pseudovirion capsid.  [A] Micrograph of HPV16 PsV imaged by cryo-EM bound to holey thin carbon. 
Scale bar 100 nm. [B] Three-dimensional reconstruction of HPV16 PsVs demonstrating the pentameric 
capsomeres, icosahedral symmetry and spherical HPV16 PsV capsid. The L1 protein model (PDB  ID: 
5kep) was docked into the 3D density map (50). [C] Fourier Shell Correlation curve demonstrating 
achieved resolution in HPV16 PsV density map. The resolution the map was assessed where the 






3.3 Production and purification of furin cleaved and uncleaved 
HPV16 PsVs for high resolution cryo-EM 
HPV16 PsVs were cleaved by the addition of exogenous furin (section 2.4) to enable direct 
visualisation of the resulting physical changes to the HPV capsid after furin cleavage. 
Additionally, furin uncleaved HPV16 PsVs were used as a negative control for the effects of 
furin on the HPV16 capsid. Successful capsid protein expression and furin cleavage of L2 was 
demonstrated by SDS-PAGE and silver staining, indicating a double L2 band at ~75 kDa within 
the furin processed PsVs, compared to the furin unprocessed HPV16 PsVs (Figure 3.3[A]). 
Incomplete furin cleavage appears to be the norm (105, 126). Subsequently, the furin cleaved 
HPV16 PsVs were tested for infectivity in HeLa cells. HeLa cells infected with either furin 
uncleaved and cleaved pseudovirions exhibited higher luciferase readings than uninfected 
cells, indicating the luciferase reading was not due to background signal (Figure 3.3[B]). 
Moreover, virions cleaved by exogenous furin were much more infectious than uncleaved 
virions (Figure 3.3[B]). High-resolution cryo-EM micrographs of furin cleaved and uncleaved 
HPV16 capsids displayed spherical virions with capsomere protrusions (Figure 3.3[C] and 
[D]). These micrographs also demonstrated that both furin cleaved and uncleaved HPV16 
PsVs were structurally homogenous and maintained the expected spherical 55 nm capsid 















Figure 3.3. Successful generation and evaluation of furin cleaved HPV16 PsVs. [A] SDS-PAGE 
demonstrating successful furin cleavage of L2 at ~ 75 kDa, illustrated by the double L2 band ‘(+ furin)’ 
lane, compared to the single L2 band in the ‘(-furin)’ lane. [B] HeLa cells were infected with either furin 
cleaved or uncleaved HPV16 PsVs and Gaussia luciferase luminescence was measured 48 hours later 
as a read-out for infection. Luciferase values are presented as x-fold change relative to uninfected HeLa 
cells, which was set to 1. Bars depict mean values, while error bars indicate standard error of the mean. 
Cryo-EM images of [C] furin uncleaved HPV16 PsVs and [D] furin cleaved HPV16 pseudovirions 
illustrate homogenous, spherical ~55nm capsids with no distinguishable structural differences between 




3.4 High-resolution cryo-EM density maps  
After sample vitrification, high-resolution imaging (section 2.11), and single particle analysis 
(sections 2.12 and 2.13), we produced two 3D reconstructions of the HPV16 PsV capsid; a 
furin uncleaved HPV16 PsV reconstruction (Figure 3.4 [A, C] and a furin cleaved HPV16 PsV 
(Figure 3.4 [B, D]) reconstruction at 7.29 Å and 5 Å, respectively (Table 3.5 and Table 3.6). 
The single-particle analysis and intermediate structures are presented in Figure 2.1 and Figure 
2.2. The resolution values were calculated according to the ‘gold-standard’ Fourier Shell 
Correlation (FSC) (Figure 3.4 [C] and [D]) (178, 179). The density maps display a continuous 
‘shell’ of protein density made up of pentameric hexavalent or pentavalent capsomeres, on a 
T=7 spherical capsid with a diameter of ~ 55 nm (Figure 3.4 [A] and [B]). Both capsids contain 
72 capsomeres arranged with icosahedral two-fold, three-fold and five-fold symmetry. The 
capsids were composed of sixty asymmetric units and no differences in capsid diameter were 
observed, when comparing the furin cleaved and uncleaved HPV16 capsid (Figure 3.4 [A] and 
[B]). At the achieved resolution of 5 Å and 7.29 Å, some secondary structural features could 
be resolved in both maps and both reconstructions were at sufficient resolution to determine 
the position, orientation, and conformation of each L1 chain (PDB ID: 5kep) within the capsid 
structure (Figure 3.5). Alpha helices and beta sheets within each L1 chain (PDB ID: 5kep) 















Table 3.2 Cryo-EM data collection parameters, refinement and validation statistics for the furin 
uncleaved HPV16 PsV dataset. 
Data collection parameters 
Microscope Titan Krios 
Detector K3  
Voltage (kV) 300 
Pixel size (Å) 0.53 
Nominal magnification 81 000 
Defocus range (µm) -0.75, -1.0, -1.25,-1.5,-1.75,-2.0 
Total dose (e-/Å2) 45 
Exposure time (s) 4.01 
Dose per fraction (e-/Å2) 1 
Number of images collected 9 464 
Number of frames per image 45 
Microscope parameters 
C2 aperture (µm) 70 
Objective aperture (µm) 100 
Cs (mm) 2.7 
Map reconstruction 
Initial particle number  20 595 
Final particle number 3 913 
Particle box size (voxel) 750 
Resolution (gold standard FSC = 0.143) (Å) 7.29 
Map sharpening β factor (Å2) -20 





Table 3.3 Cryo-EM data collection parameters, refinement and validation statistics for the furin 
cleaved HPV16 PsV dataset. 
Data collection parameters 
Microscope Titan Krios 
Detector K2  
Voltage (kV) 300 
Pixel size (Å) 1.048 
Nominal magnification 130 000 
Defocus range (µm) -0.75, -1.0, -1.25,-1.5,-1.75,-2.0 
Total dose (e-/Å2) 45 
Exposure time (s) 7.5 
Dose per fraction (e-/Å2) 1 
Number of images collected 4 162 
Number of frames per image 45 
Microscope parameters 
C2 aperture (µm) 70 
Objective aperture (µm) 100 
Cs (mm) 2.7 
Map reconstruction 
Initial particle number  20 549 
Final particle number 3 913 
Particle box size (voxel) 750 
Resolution (gold standard FSC = 0.143) (Å) 5 
Map sharpening β factor (Å2) -95 

















Figure 3.4. Structure of HPV16 PsVs imaged by cryo-electron microscopy (cryo-EM) achieved 
high- resolution. Surface rendered three-dimensional density maps of [A] furin uncleaved (- furin) and 
[B] furin cleaved (+ furin) HPV16 PsVs confirm spherical capsid structure and pentameric capsomers 
arranged according to icosahedral symmetry. No difference in capsid diameter after furin cleavage was 
observed. Scale bar 100 Å. Fourier Shell Correlation curve demonstrating achieved resolution in the 
[C] furin uncleaved and [D] furin cleaved HPV16 PsV density maps. The resolution of each map was 
assessed where the Fourier Shell curve crossed a correlation value of 0.143, according to the ‘gold-












Figure 3.5. Secondary structures within the L1 capsid protein were identified in both density 
maps. Central sections through the cryo-EM density map of [A] furin uncleaved and [B] furin cleaved 
HPV16 PsVs, illustrate the quality of the reconstructions. The outer surface is less defined relative to 
the internal surface. Scale bar 100 Å. The atomic structure (PDB ID 5kep) of the L1 capsid protein was 
docked into the [C] furin uncleaved and [D] furin cleaved HPV16 PsV density maps, demonstrating that 
the resolution obtained was sufficient for determining the orientation and conformation of each L1 chain 
making up the capsid. Representative regions of secondary structures are shown to illustrate goodness 





3.5 Furin cleavage of L2 triggers a conformation change in the L1 
chains within the HPV16 capsid 
Cleavage of L2 by furin is suggested in the literature to enable conformation changes in the 
HPV16 capsid necessary for later infection steps (section 1.5.2), but this has never been 
directly visualised. There is an unknown number of L2 molecules within the HPV16 capsid and 
their location within the capsid is inconclusive (55, 130). Consequently, we could only assess 
structural changes to the L1 capsid protein. There were no obvious differences in capsomere 
structure, arrangement or capsid diameter identified between the furin uncleaved and furin 
cleaved density maps (Figure 3.4). To assess changes in the arrangement of the L1 proteins 
after furin cleavage, we rigid-body docked the individual L1 protein chains (PDB ID: 5kep) into 
either the furin uncleaved or furin cleaved HPV16 PsV density maps generated here, without 
alignment of the L1 chain A (section 2.16). After which, each L1 chain within both pentavalent 
and hexavalent capsomeres was in a different position after furin cleavage (Figure 3.6). The 
change in position of the L1 chains was independent of other L1 chains, and the whole 
capsomere does not rotate or translate in a particular direction (Figure 3.6). Chain A (forming 
part of the pentavalent capsomere) was then aligned to assess the conformation change 
relative to a fixed point. Each capsomere has an altered position relative to adjacent 
capsomeres, and the central cavity within each capsomere expands after furin cleavage 
(Figure 3.7 and Figure 3.8). The canyon between a pentavalent and hexavalent capsomere is 
reported to be the site of heparin binding (50). Therefore, this region on the HPV16 capsid is 
of particular importance for assessing the functional implications of a furin mediated capsid 
conformation change for later steps in HPV16 infection. We then focussed our investigation 
on this region of the HPV16 capsid, using the asymmetric unit of the HPV16 capsid (PDB ID: 
5kep; Figure 1.2), as this represents all the positions of the L1 chains on the HPV16 capsid. 
To assess the change in capsomere conformation after furin cleavage, the asymmetric unit in 
the furin uncleaved and cleaved conformation were superimposed, and chain A was aligned 
between the two conformations (Figure 3.7[A]). The RMSD was calculated for each chain 
(chains A to F) (Figure 3.7[A] and Table 3.4). Across all six L1 chains, the RMSD was 0.940 
Å, with chain E displaying the greatest movement, at 1.677 Å and chain C displaying the least 
movement after furin cleavage, at 0.762 Å (Table 3.4). In the putative heparin binding site, the 
L1 chains shifted on average 0.4 Å after furin cleavage (Figure 3.9). These results complete 
objective 1.2 and 1.3.  
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Figure 3.6. Atomic model reveals changes in the positioning of L1 chains within both 
pentavalent and hexavalent capsomeres after furin cleavage.  Each L1 chain within a published 
L1-only HPV16 asymmetric unit (PDB ID 5kep) was docked individually into [A] hexavalent and [B] 
pentavalent capsomere position within the furin uncleaved (blue) and furin cleaved (magenta) density 
maps generated here. This was done without alignment of chain A (forming the pentavalent 
capsomere), demonstrating that both the pentavalent and hexavalent capsomere display altered 
conformations after furin cleavage. Black arrows demonstrate the movement of the L1 chains after furin 
cleavage. The blue hexagon indicates a hexavalent capsomers, while the orange pentagon indicates a 




Figure 3.7. Atomic model reveals changes in the positioning of L1 chains after furin cleavage 
occurs in the HPV16 asymmetric unit. Each chain within a published L1-only HPV16 asymmetric unit 
(PDB ID 5kep) was docked into either the furin uncleaved (magenta) and furin cleaved (blue) 
conformation based on the density maps produced in this study. L1 chain A forming part of the 
pentavalent capsomere was aligned between the furin uncleaved and furin cleaved for quantitative 
assessment of the conformation changes of the other chains (B to F) after furin cleavage. [A] The L1-
only asymmetric unit (PDB ID: 5kep) in either the furin uncleaved (magenta) or furin cleaved (blue) 
conformation. Each L1 protein chain within the asymmetric unit is labelled as A to F. Black arrows 
indicate the direction of movement of each L1 chain after furin cleavage. The blue hexagon indicates a 
hexavalent capsomere. [B] Video of the change in asymmetric unit (PDB ID: 5kep) conformation after 
furin cleavage. The L1-only asymmetric unit (PDB ID: 5kep) in either the furin uncleaved (magenta) or 









Figure 3.8. Atomic model reveals changes in the positioning of L1 chains after furin cleavage 
occurs across the HPV16 capsid. Each chain within a published L1 only HPV16 asymmetric unit 
(PDB ID: 5kep) was docked into the furin uncleaved (magenta) and furin cleaved (blue) conformation 
based on the density maps produced in this study. Chain A forming part of the pentavalent capsomere 
was aligned between the furin uncleaved and furin cleaved L1 capsomeres. [A] Pentavalent capsomere 
surrounded by five other capsomeres and [B] hexavalent capsomere surrounded by six other 
capsomeres, reveal the movement of L1 chains around these regions on the HPV16 capsid after furin 
cleavage. [C] Video of the capsid conformation change after furin cleavage. The furin uncleaved 
conformation is indicated in magenta, while the furin cleaved conformation is indicated in blue. This 





Table 3.4. Quantification of HPV16 L1 chain movement after furin cleavage show each  L1 
chain display different degrees of movement.  
Chain ID RMSD (Å) 
Chain A 0.000 
Chain B 0.781 
Chain C 0.762 
Chain D 1.317 
Chain E 1.677 
Chain F 1.105 
Average 0.940 
 
3.6 HPV16 binds to heparin 
After furin cleavage of L2, rearrangement of the L1 chains in the pentavalent and hexavalent 
capsomere was observed, including around the putative heparin binding site on the HPV16 
capsid (Figure 3.9) (50). Therefore, we assessed whether the observed rearrangement of L1 
chains after furin cleavage had any effect on HPV16 binding to heparin, using the molecular 
dynamics program ISOLDE (section 2.17) (180), the high-resolution HPV16 density maps 
produced here (Figure 3.4[A] and [B]). An anionic aspartic acid peptide was used as a 
substitute for heparin, as heparin is highly heterogenous, to broadly characterise the effects 
of furin cleavage on HPV16 binding to a negatively charged molecule. An overview of the 
results is presented in Figure 3.10. After running the simulation at 310 Kelvin, the anionic 
peptide formed hydrogen bonds to the side chains of the positively charged amino acids lysine 
(lys), arginine (arg) and histidine (his) on the L1 chains in the furin uncleaved and furin cleaved 
conformation (Figure 3.11, Table 3.5 and Table 3.6). Lys54, lys59, lys171, lys361, arg365, 
his431 on the L1 chains in furin uncleaved conformation all formed hydrogen bonds with the 
anionic peptide (Table 3.5), while on the L1 chains in the furin cleaved conformation lys59, 
lys430 and his431 formed hydrogen bonds with the anionic peptide (Table 3.6). Additionally, 
the peptide formed hydrogen bonds with polar amino acids on the L1 chain, including serine 
(ser), threonine (thr), asparagine (asn) and glutamine (gln), and non-polar amino acids 
including cysteine (cys), proline (pro) and isoleucine (ile) (Figure 3.11, Table 3.5 and Table 
3.6). Ile60, ser173, cys175, thr176, asn177,cys365, cys428, gln429 and thr432 on the L1 
chains in the furin uncleaved conformation formed hydrogen bonds with the anionic peptide, 
while thr176, thr432, asn177, gln429, cys428, cys175 on the L1 chains in the furin cleaved 
conformation formed hydrogen bonds to the anionic peptide (Table 3.5 and Table 3.6). 
Notably, the L1 amino acids contributing to the aspartic acid binding originated from each of 
the three different L1 chains (chains A, B and F) around the canyon between the pentavalent 
and hexavalent capsomere. The majority of L1 amino acids binding the aspartic acid peptide 
were located on chain A, forming part of the pentavalent capsomere (Figure 3.11, Table 3.5 
and Table 3.6). Fewer hydrogen bonds were observed between the L1 amino acids and the 
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anionic peptide after furin cleavage (compare Figure 3.11[A, B] to [C, D]; Table 3.5 to Table 
3.6). These results complete objective 2.1. 
 
Figure 3.9. Furin cleavage of L2 causes a change in capsomere conformation around the 
putative heparin binding site. Cryo-EM suggests that heparin (surface rendered in grey) binds one of 
the (identical) L1 chains (chain A) in the pentavalent capsomere (indicated by an orange pentagon) and 
chains B and F within the hexavalent capsomere (indicated by a blue hexagon) (50). [A,B] The 
observed change in capsomere conformation, indicated by black arrows, between furin uncleaved 
(magenta) and furin cleaved (blue) also occurs around the heparin binding site. [C] Video of the 
conformation change after furin cleavage, around the heparin binding site. The furin uncleaved 
conformation is indicated in magenta, while the furin cleaved conformation is indicated in blue. This 




Figure 3.10. HPV16 L1 chains form hydrogen bonds with a highly negatively charged peptide.  
 Three L1 chains (chains A, B and F) of the HPV16 asymmetric unit (PDB ID: 5kep) fitted into [A] the 
furin uncleaved (magenta) and [B] the furin cleaved (blue) HPV16 pseudovirion density maps produced 
here. An anionic peptide (grey) was used as a heparin substitute and docked into the putative heparin 
binding site (50). Orange pentagon indicates a pentavalent capsomere, while the blue hexagon 




Figure 3.11. HPV16 L1 amino acids before and after furin cleavage forming hydrogen bonds with 
an anionic peptide docked into the putative heparin binding site. The three L1 chains (PDB 
ID:5kep) for the furin uncleaved HPV16 PsVs are indicated in magenta in [A] and [B], while the furin 
cleaved HPV16 PsV L1 chains (PDB ID:5kep) are indicated in blue in [C] and [D]. The side chain of 
each interacting amino acid is shown and is labelled with the three letter residue name and L1 chain 
location (chain A, B or F). The aspartic acid peptide is coloured in grey while the hydrogen bonds are 




Table 3.5. HPV16 L1 amino acids interactions before furin cleavage of L2. Shown are the amino 
acids on HPV16 L1 proteins in the furin uncleaved capsid conformation, which interact with an aspartic 
acid peptide docked into the putative heparin binding site. 
Chain A Chain B Chain F 
lys54 lys171 lys59 
lys361 ser173 ile60  
tyr363 cys175 arg365 
arg365 thr176  cys428 
ile426 asn177 gln429 
cys428 cys365  
gln429   
his431   
thr432   
 
Table 3.6. HPV16 L1 amino acids interactions after furin cleavage of L2. Shown are the amino 
acids on L1 proteins in the furin cleaved HPV16  conformation, which interact with an aspartic acid 
peptide docked into the putative heparin binding site. 
Chain A Chain B Chain F 
lys59 cys175 gln429 
his431 thr176 cys428 
cys428 asn177 lys430 
gln429  his431 




3.7 Attempt at locating L2 within the furin uncleaved and furin 
cleaved density maps 
Unfortunately, even at the resolution achieved, we were unable to resolve non L1 protein 
density (section 2.18) which may potentially correspond to the L2 protein, within either our 
furin uncleaved or furin cleaved density maps (data not shown). Given that no study to date 
has definitively demonstrated the location of the entire L2 protein within the HPV capsid, this 
result was not unexpected.   
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4 Discussion 
Persistent infection with high-risk HPV types is associated with several cancers, especially 
cervical cancer, which is prevalent in areas of the world with high HIV/AIDS prevalence like 
South Africa (5, 8, 17, 20, 21). Prophylactic vaccines for HPV are available and safe but have 
some shortcomings including limited HPV type cross-protection, unknown long-term efficacy, 
cost, and accessibility (32, 33, 36, 44, 45). Despite considerable efforts by HPV vaccination 
programs both in South Africa and globally, cervical cancer remains a leading cause of cancer 
deaths in women worldwide (20). This highlights the need for the development of additional 
therapies to decrease the burden of HPV infection and HPV-linked cancers worldwide.  
A potential therapeutic target is preventing HPV entry mechanisms used by the virus to infect 
cells. To initiate infection, HPV16 is primed for virus entry by several host proteins, including 
initially binding to HSPGs on the cell surface followed by enzymatic processing, most notably 
by furin. Without furin cleavage of the L2 capsid protein, HPV has far reduced infectivity in 
HeLa cells (Figure 3.3[B]) and is non-infectious in furin deficient cell lines. This indicates furin 
processing is an essential step in HPV infection (87, 99, 106, 109, 110, 112, 126).It is 
proposed, using antibody neutralisation assays, the furin cleavage of L2 facilitates a change 
in capsid structure, although this has never been directly visualised. Therefore, the present 
study focussed on direct visualisation of the effects of furin on the HPV16 PsV capsid. 
Clarifying the impact of this protease on the HPV16 capsid using structural biology may aid in 
the development of novel therapeutics against this prevalent and oncogenic virus. To achieve 
this, biochemical characterisation, cryo-electron microscopy, single particle analysis and 
molecular dynamics were applied in this study to describe the physical effects of furin cleavage 
on the HPV16 capsid. Here we describe the first furin cleaved HPV16 PsV structure, at 5 Å 
resolution. 
4.1 HPV16 pseudovirions were suitable for high-resolution electron 
microscopy and single particle analysis 
HPV16 PsV production and purification, followed by SDS-PAGE, silver staining, HeLa cell 
infection and HaCaT cell antibody neutralisation indicated HPV16 had been successfully 
produced and were suitable for downstream single-particle analysis (Figure 3.1[A] and [B]). 
The HPV16 PsVs which (per definition) encapsidated a pseudogenome (i.e. a reporter gene 
plasmid) exhibited T=7, spherical and ~55 nm capsid structures as seen for both 
pseudovirions and native HPV (4, 47, 49, 50, 67, 69, 126, 159, 160) displayed 
homogenous capsid morphology and were well distributed on the TEM grid (Figure 3.1[C], 
Figure 3.2[A]). We noted that the uranyl acetate negative stain penetrated some of the virions, 
causing them to appear ‘dented’ on micrographs (Figure 3.1[C]). These virions may be 
empty particles, containing no plasmid DNA and 
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therefore easily stained (49). However, the majority of HPV16 PsVs imaged were suitable for 
TEM imaging and single particle analysis. Apparent conformation changes to proteins due to 
adherence to plastic is a known issue in HPV research (128, 163). The risk of capsid 
conformation changes due to adherence to plastic was minimised by using siliconized 
Eppendorf tubes during pseudovirion production and the furin cleavage experiments. Taken 
together, the experimental conditions and virion quality was consistent with published results 
and demonstrate the purity, infectivity, and type-specificity of the HPV16 PsVs produced here 
(4, 47, 49, 50, 67, 69, 126, 159, 160). 
The initial low-resolution HPV16 PsV reconstruction demonstrated the expected capsid 
structure and morphology, with 72 pentameric capsomeres, arranged as either hexavalent or 
pentavalent capsomeres and organisation around two-fold, three-fold, or five-fold icosahedral 
axes of symmetry (Figure 3.2[B]). Likewise, the high-resolution reconstructions of both furin 
uncleaved and cleaved HPV16 PsVs also display these characteristics (Figure 3.4[A] and [B]). 
Additionally, secondary structural features such as alpha helices and portions of the central β 
jelly-roll could be distinguished from the density in both high-resolution reconstructions (Figure 
3.5[C, D]). L1 protein surface loops and C-terminus arms extending from each pentamer could 
not be resolved in either of the two high-resolution density maps produced here, as these are 
the most flexible regions within the HPV capsid (50, 55, 56, 183). Indeed, the less defined 
density on the capsomere surface of both the furin uncleaved and furin cleaved 
reconstructions likely reflect the inherent flexibility of the surface loops on individual 
capsomeres (Figure 3.4[A.B]).  
After HPV16 binding to cell-associated HSPGs and capsid processing by host cyclophilins 
and kallikrein-8, furin cleaves the exposed N-terminus region on L2, reportedly leading to a 
change in the arrangement of the L1 and L2 capsid proteins (106, 110). Furin cleavage only 
removes about twelve amino acids off the L2 protein, which we visualised as a slightly lower 
band compared to uncleaved L2 on SDS-PAGE (Figure 3.3[A]). Incomplete furin cleavage is 
expected since complete furin cleavage of L2 has not been observed in the intact HPV capsid 
(99, 105, 106, 112, 126). The incomplete cleavage of L2 that we observed may be due to 
either all HPV16 capsids being partially cleaved by furin, or a subset of capsids being fully 
cleaved (112) Regardless, incompletely furin cleaved capsids still indicate that some of the L2 
N-termini are exposed on the capsid surface and furin cleaved HPV16 PsVs were still highly 
infectious compared to uncleaved HPV16 PsVs (Figure 3.3[B]) (126). Becker et al. have 
demonstrated that only furin cleaved L2 proteins could be detected in the infected cell’s 
nucleus, while furin uncleaved L2 proteins remain within the endosome. This indicates 
incomplete furin cleavage of L2 is sufficient for infection and that HPV16 PsVs cleaved by 
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exogenous furin have the same infectious pathway as HPV16 PsV infection of cells expressing 
furin and cell surface HSPGs (105). Therefore, even though we observed incompletely furin 
cleaved L2 within the HPV16 PsV capsid, this may represent a natural infection in vivo. 
 
4.2 Conformational changes to the HPV16 capsid after furin 
cleavage 
To investigate changes in the HPV capsid which may occur after furin cleavage of L2, we 
compared the two high-resolution reconstructions of furin uncleaved and cleaved virions 
produced here (Figure 3.4[A] and [B]), by rigid-body docking all six of the L1 chains in the 
atomic model of the HPV16 asymmetric unit (PDB ID: 5kep). This would allow us to interpret 
the differences in overall capsomere positioning between the two density maps to atomic 
resolution, providing us with better insight into the biological mechanism of HPV16 entry into 
host cells. The conformation changes to the L1 proteins visualized here after furin cleavage 
occurred across the HPV capsid, rather than stochastically or localised to a specific 
capsomere (Figure 3.8). Changes in quaternary structure across the entire viral capsid may 
explain the slow exposure of the L2 N-terminus and the observation that furin cleavage of L2 
is the rate-limiting step in HPV entry (87, 105). The 0.940 Å change in the positioning of L1 
chains after furin cleavage observed was not surprising as electron microscopy of furin 
uncleaved and furin cleaved HPV16 PsVs revealed no obvious changes in overall capsid 
structure when viewed by TEM (Figure 3.3[C, D] and Table 3.4), consistent with previous 
research (126, 127). Our results add direct evidence to the hypothesis that the furin cleaved 
HPV16 capsid is an intermediate structure between binding and entry (105).  
Many viruses exploit furin for proteolytic processing during host cell entry, using furin mediated 
changes in capsid proteins to enhance infectivity, and HPV may be no exception (97, 106, 
115, 120-123, 184). Indeed, there is indirect evidence that L1 protein chains within the HPV 
capsid undergo a conformation change after furin cleavage of L2, as we confirmed by cryo-
EM (Figure 3.6, Figure 3.7, Figure 3.8, Figure 3.9 and Table 3.4) (87, 93, 105, 112, 127, 128, 
132, 158). Most studies infer a conformation change in L1 after furin cleavage based on the 
RG-1 antibody detection of a previously unexposed region on L2 (amino acids 13-36). This 
region on L2 is only exposed after furin cleavage, as RG-1 only immunoprecipitated furin 
cleaved HPV16 PsVs. Likewise, HPV16 PsVs bound to HaCaT cells treated with a furin 
inhibitor could not bind RG-1, indicating furin is the vital host molecule necessary to expose 
the N-terminus region of L2. L1 protein(s) likely occlude the L2 N-terminus as two antibodies 
(H16.V5 and H16.E70) with epitopes on the HPV16 L1 protein prevent exposure of the RG-1 
binding site, after the virus-antibody complex was added to cells, although the antibody did 
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not prevent HPV binding to the cell surface (87, 105, 112, 127, 128, 132, 158). Similarly, two 
other L1 specific antibodies, H16.56E and H33.J3, allow virion binding to HeLa cells and 
internalisation, but inhibit intracellular infection. These antibodies possibly achieve this by 
preventing furin-associated conformational changes to the HPV capsid necessary for later 
steps in infection (92). Unfortunately, these antibody binding studies do not distinguish 
between structural changes to the L1 proteins upon cell surface binding and the L1 
conformation change after furin cleavage, making definitive conclusions difficult. Additional 
studies of the binding capacity of the antibodies mentioned above to furin cleaved HPV16 
PsVs may help clarify this uncertainty.  
Other cellular proteins such as kallikrein-8 are also responsible for changes in the capsid 
during HPV16 entry (section 1.5.2 and 1.5.3) (105, 132). It is therefore likely that the 
conformational changes visualised here after furin cleavage in combination with conformation 
changes induced by other host proteins prepare the virus capsid for internalisation and/or 
uncoating. Notably, furin cleaved HPV16 capsids are considered to be in the final conformation 
necessary for infection (56, 105).  
The observed structural changes in the furin cleaved HPV16 PsV capsid obtained here occur 
both within capsomeres and between capsomeres (Figure 3.6, Figure 3.7, Figure 3.8, Figure 
3.9 and Table 3.4). The exact function of the conformation change in the L1 proteins is 
presently unknown. However, the region of the L2 N-terminus which is now exposed is 
important for intracellular infection steps, and some research has found that this region on L2 
is important for binding to the secondary cell receptor, although this is still inconclusive (110, 
130, 131). Alternatively, the L1 conformation change after furin cleavage of L2 may begin the 
viral capsid uncoating process at the cell surface (103). An additional function of the L1 
conformation change after furin cleavage of L2 may be that this processing affects the affinity 
of the virus capsid for HSPGs (or heparin),  allowing the transfer of the HPV16 capsid to the 
elusive entry receptor or receptor complex (92, 93, 103). Indeed, HPV VLPs disassembled 
into individual capsomeres displayed no binding to cells, indicating that the entire capsid with 
intercapsomere contacts must be necessary for infection (89). Potentially the changes in 
capsomere structure and altered position of any capsomere relative to its’ neighbours obtained 




4.3 HPV16 binds to an anionic peptide within a putative heparin 
binding site 
Heparin is a widely accepted substitute molecule for structural biology studies of the 
interaction between cell surface HSPGs and HPV (41, 50, 102, 103). Unfortunately, both 
heparin and HSPGs are flexible and heterogeneous molecules which do not have molecular 
dynamics force fields within programs such as ISOLDE. To circumvent this, we generated an 
anionic peptide, to simulate the negative surface charge and length of heparin, which was rigid 
body docked into a possible heparin-binding site in the canyon between hexavalent and 
pentavalent capsomeres (section 2.17) (50). In both the furin uncleaved and furin cleaved 
conformations, the amino acids on L1 interacting with the negatively charged peptide formed 
binding patches composed of more than a single L1 chain. These L1 chains originated from 
both hexavalent (chains B and F) and pentavalent (chain A) capsomeres (Figure 3.10, Figure 
3.11, Table 3.5 and Table 3.6) similar to heparin binding results obtained by others (50, 102, 
103).  
The majority of L1 amino acids binding the anionic peptide in both furin cleaved and uncleaved 
structures were located on chain A, corroborating with heparin density located around the 
pentavalent capsomere (50). Furthermore, many of the of L1 amino acids forming binding 
patches to the anionic peptide were positively charged or polar amino acids (Figure 3.11, 
Table 3.5 and Table 3.6). In the L1 chains of the furin uncleaved conformation, we identified 
several amino acids forming hydrogen bonds to the anionic peptide, including lys59, thr176, 
and asn177 originating from the L1 chain within the hexavalent capsomere and cys428, 
gln249, his431 and thr432 from the L1 chain within the pentavalent capsomere (Figure 3.11 
and Table 3.5). The specific amino acids listed here are identical to the HPV16 L1 amino acids 
interacting with heparin identified by Guan et al. (50). This confirms the suitability of the anionic 
peptide as a heparin substitute. Our results in combination with Guan et al. suggest these 
amino acids are required for viral capsid binding to HSPGs (50). Our molecular dynamics 
result also proposes that HPV16 binding to heparin (and potentially HSPGs) depends on the 
arrangement of these interacting L1 amino acids in relation to one another and overall charge 
distributions, as suggested by Knappe et al. (69), rather than the competing hypothesis that 
defined structural features on heparin and HSPGs mediate HPV binding (93).  
Contrary to our results and results obtained by Guan et al. (50), x-ray crystallography studies 
suggest heparin binds to the surface and vertically to the side wall of the capsomere, rather 
than horizontally between capsomeres (50, 102). As we presumed heparin binds horizontally 
in the canyon between capsomeres, it is not surprising that our results did not correlate to 
those obtained by x-ray crystallography. The x-ray crystallography studies made use of HPV 
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pentamers, rather than the entire HPV capsid. Consequently, it is unknown whether the 
described binding sites occur on the hexavalent or pentavalent capsomeres, and 
intercapsomere contacts potentially relevant for heparin binding may be absent (102). 
Interestingly, although the anionic peptide was docked horizontally into the heparin density 
prior to molecular dynamics during our investigation, the peptide was free to move within the 
canyon between capsomeres during the simulation. But we did not observe the peptide 
binding vertically to the L1 chains in either the furin cleaved or uncleaved conformation (Figure 
3.10). However, initially docking the peptide horizontally into the heparin density may have 
biased the results. A further simulation with the peptide docked vertically along the capsomere 
wall may resolve this query.  
As atomic level crystallography studies (102, 103) indicate several heparin-binding sites on 
the capsomeres, the heparin density resolved by cryo-EM (50) may represent the average 
density of all possible binding sites of heparin to the capsids. Consequently, discrepancies 
between the amino acids involved in heparin-binding between the crystal structures and 
published cryo-EM structure may be explained by this. Moreover, it is proposed that HPV16 
makes use of several binding sites on L1 during entry and infection, therefore a combination 
of the heparin binding amino acids identified from crystal studies and cryo-EM studies might 
be used for successful HPV infection (102, 103). Our results also support this conclusion, as 
the simulation revealed two anionic peptide binding sites (one on either side of the 
intercapsomere ‘canyon’) in both the furin uncleaved and furin cleaved L1 conformation 
structures (Figure 3.9 and Figure 3.10). Consequently, the structural changes to the L1 capsid 
proteins observed after furin cleavage may reduce HPV16 binding to the initial HSPG cell 
surface receptor, allowing transfer to secondary HSPG sites on the cell, possibly forming part 




4.4 Furin cleavage may reduce HPV16 binding to heparan sulphate 
proteoglycans  
To assess whether furin cleavage alters the affinity of the L1 amino acids for the anionic 
peptide (the HSPG substitute molecule), we measured hydrogen bond formation between the 
L1 amino acids and the anionic peptide before and after furin cleavage. Our molecular 
dynamics analysis indicated that after furin cleavage the amino acids originating from L1 
chains in the furin cleaved conformation had fewer hydrogen bonds to the anionic peptide, 
when compared to the amino acids on the L1 chains within the uncleaved conformation 
(compare Figure 3.11[A, B] to [C, D]; and Table 3.5 to Table 3.6). This result proposes that 
HPV16 has decreased affinity for the primary cell surface HSPG receptor after furin cleavage. 
In line with this, HPV16 PsVs processed by furin have reduced affinity to heparin and were 
found to dissociate from HSPGs on COS-7 cells (92, 105). Additionally, furin cleaved HPV16 
PsVs can infect HSPG deficient cell lines, illustrating HSPG independent infection after furin 
cleavage (99, 126).  
The molecular dynamics results also suggest that after furin cleavage, HPV16 PsVs make use 
of different L1 amino acids to interact with the negatively charged peptide (compare Figure 
3.11[A, B] to [C, D]; and Table 3.5 to Table 3.6), although these L1 amino acids are all located 
on the L1 chains surrounding the intercapsomere canyon (Figure 3.10). This result is similar 
to other research suggesting HPV16 may attach to heparan sulphate molecules using different 
binding sites on the capsid to achieve either initial attachment to cells or later steps in the entry 
process (92, 102, 103). Consequently, molecular dynamics results also propose HPV16 does 
not dissociate from the HSPG substitute, after furin cleavage, but rather uses different amino 
acids on the L1 chains for subsequent steps in infectious entry (Figure 3.10 and Figure 3.11), 
as observed by others (92, 102, 103). Furin cleaved HPV16 PsVs are independent of HSPGs 
used for initial cell binding, compared to furin uncleaved virions (99, 109, 110). However, two 
other highly sulphated polysaccharides, carrageenan and heparin, both inhibited HPV16 
infection (127). This result may indicate a further role of sulphated polysaccharides in infection 
after furin cleavage, although the initial cell surface binding HSPGs become unnecessary. 
Moreover, HPV33 VLPs bind strongly to HeLa cells, with a dissociation constant of 84 pM. 
This indicates a strong association, possibly by HPV33 binding to cell surface HSPGs. As a 
result, complete dissociation of the viral capsid after furin cleavage is less likely (89).  
Even though all capsomeres on the HPV capsid are composed of five L1 chains (41, 50, 102),  
there are differences in the interactions between the two sets of capsomeres. The interface 
between a hexavalent and pentavalent capsomere is on the icosahedral five-fold axis of 
symmetry, where a single L1 chain of the pentavalent capsomere only contacts a single L1 
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chain on the hexavalent capsomere (Figure 1.1[B]). In contrast, the interface between the two 
hexavalent capsomeres is asymmetric, although it appears to have six-fold symmetry (‘pseudo 
six-fold symmetry’) (Figure 1.1[B]).  Three L1 chains contact within the hexavalent capsomere 
interact with four neighbouring capsomeres, while the other two L1 chains within the 
hexavalent capsomere contact the remaining two surrounding capsomeres (Figure 1.1 [B]) 
(48, 50). These differences have functional consequences for HPV infection, as Guan et al. 
only resolved heparin density in the canyons between the pentavalent and hexavalent 
capsomere, and no heparin density within the canyon between two hexavalent capsomeres 
(Figure 3.9) (50). The C-terminus of L1 proteins, within the canyon between capsomeres,  
contain a cluster of basic amino acids, which may be used by the virus during attachment to 
cell surface HSPGs (47, 52, 69, 94) (94). Speculatively, the L1 C-terminus originating from 
hexavalent capsomeres may be less exposed in the canyons between hexavalent 
capsomeres when compared to the C-terminal arms originating from the pentavalent 
capsomere, due to the pseudo six-fold symmetry between two hexavalent capsomeres. 
Alternatively, the addition of a sixth capsomere around the hexavalent capsomere may disrupt 
HSPG binding sites which are present between a pentavalent and hexavalent capsomere. 
Interestingly, the majority of the L2 protein could be located within the pentavalent capsomere, 
with some regions (eg. The N-terminus) being surface exposed around the pentavalent 
capsomere (52, 60). It is conceivable that the surface exposed regions of L2 may also contact 
the cell surface HSPGs during virus entry, which may explain why heparin (or HSPGs) only 
binds around the pentavalent capsomere. Indeed, an L2 peptide composed of the N-terminus 
amino acids was found to bind to the cell surface and internalise into the cell (58, 131). 
However, other studies indicate that L2 is unlikely to be involved in cell-surface binding (59, 
89). More studies of the possible interaction between HPSGs and the L2 capsid protein will 
be needed to clarify this.  
As the identity, location and amount of the secondary entry receptor or receptor complex on 
the keratinocyte cell surface is speculative (section 1.5.3), it is unknown whether furin 
cleavage of L2 allows the virus to associate with this secondary receptor or receptor complex. 
Our study did not address this question but rather focused on structural changes to the HPV 
capsid before engagement with this receptor (complex). In addition, our results have the 
important caveat that a negatively charged peptide may not represent the exact sequence or 
flexibility associated with HSPGs, although we were able to replicate the negative surface 
charge on heparin, which is proposed as the primary determinant of HPV binding (69).  
77 
 
4.5 The location of L2  
Unfortunately, this investigation could not resolve any non-L1 protein density which could be 
attributed to L2, within either the high-resolution furin uncleaved or furin cleaved 
reconstructions (data not shown). Even though L2 was present in HPV16 PsV capsids and 
successfully cleaved by furin (Figure 3.3[B]). Consequently, we could not resolve the effects 
of furin cleavage on the arrangement of the L2 protein within the HPV16 capsid. The exact 
location and number of L2 proteins within the HPV16 capsid is still inconclusive. This may be 
for several reasons including heterogeneous amounts of L2 in the HPV capsids or an 
asymmetric distribution of the L2 protein within a single capsid (60, 130). These considerations 
make determining the characteristics of L2 within the HPV16 capsid using cryo-EM difficult, 
as single particle analysis generates 2D and 3D class averages and often imposes icosahedral 
symmetry, which averages out density across the whole density map (169, 172). 
Consequently, any asymmetric or heterogenous density within or between imaged particles 
that could be attributed to L2 will be weaker in the final icosahedral and averaged 
reconstruction. Asymmetric distribution of L2 within the virus capsid may also explain the 
resolution limit obtained in our density maps (Figure 3.4) and those obtained by others (50, 
60, 127). Focussed refinement of different class averages or sub-particle refinement may aid 
in determining the characteristic of L2 within HPV16 and improve map resolution. Recently 
(paper in the process of peer-review), this approach was applied to HPV16 and achieved a 
3.1 Å density map and the location of some L2 residues was determined. These L2 amino 
acids were present in the interior both of hexavalent and pentavalent capsomeres around the 
L1 protein, although the entire L2 protein was not resolved. The authors suggest L2 has a 
symmetry mismatch in the number of L2 proteins per L1 protein, and individual capsomeres 
could not incorporate five copies of L2 per capsomere, as is the case for L1, due to capsomere 
size limitations (60).  
The L2 N-terminus is apparently located in the canyon between the pentavalent and 
hexavalent capsomeres, as an antibody directed against L1 amino acids within this region, 
prevented binding of L2 specific antibodies (185). However, other studies propose the L2 N-
terminus is located near the L1 surface loops on the outer side of the capsomere as an 
antibody directed against the L1 surface loops prevented furin cleavage of L2, while a second 
antibody directed against regions of L1 within the intercapsomere canyons, did not prevent 
furin cleavage of L2 (112). It is possible that the L2 N-terminus on the capsomere exterior is 
flexible and may be located between these regions, accounting for the discrepancies between 




5 Conclusion and proposed mechanism 
Our results in combination with evidence from other studies propose a model for HPV entry 
(Figure 5.1). Importantly, other host molecules and enzymes also play a role in successful 
HPV entry (sections 1.5.2 and 1.5.3), but for simplicity, we discuss the host molecules 












Figure 5.1. Simplified proposed model of HPV16 attachment and entry into host cells.  
The HPV16 PsV (magenta) attaches to heparin (HSPG substitute molecule; surface rendered in grey) 
around the pentavalent capsomere. Furin cleaves the L2 minor capsid protein (not shown). 
Subsequently, the L1 chains on the HPV16 capsid undergo a conformation change, forming the furin 
cleaved HPV16 PsV capsid (blue). The HPV16 PsV then transfers to the secondary entry receptor or 
receptor complex, which may include the initial HSPG cell binding molecule (represented here by the 
heparin density) and is internalised into the cell. A video of this process is also available at 
https://vimeo.com/493004952/  
 
HPV16 initially binds to cell surface HSPGs using binding patches composed of positively 
charged and polar amino acids on the side wall of both the hexavalent and pentavalent 
capsomere (Figure 3.9, Figure 3.10, and Figure 3.11). This induces a conformation change 
in L1 and furin cleavage of the L2 N-terminus (not visualised here). Furin cleavage causes 
further changes in L1 protein chains within both pentavalent and hexavalent capsomeres 
(Figure 3.6) This capsid conformation change reduces the number of hydrogen bonds 
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between the L1 amino acids and the anionic peptide acting as a heparin substitute. 
Additionally, the furin mediated conformation change allows hydrogen bonds to form 
between different L1 amino acids and the anionic peptide (Figure 3.11 [C] and [D]). These 
interactions may form part of the secondary receptor complex which includes cell surface 
HSPGs and facilitates internalisation. The conformation changes after furin cleavage may 
expose previously hidden secondary cell receptor binding sites on either L1 or L2 capsid 
proteins. It appears likely that a region on the L1 capsid protein binds the secondary receptor 
(complex) as L1 only VLPs have indistinguishable binding and internalisation patterns in vivo 
and in vitro compared to L1 and L2 containing VLPs (87). Moreover, HPV may use furin 
cleavage of L2 to expose conserved amino acids on L2 which are necessary for intracellular 
infection, rather than internalisation, only after the virus has successfully bound to host cells. 
This likely evolved as an immune evasion strategy to prevent the immune system from 
detecting the conserved L2 epitope before engagement with the host cell, where it may be 
too late for the elimination of the virus (128). 
The results presented in this dissertation directly illustrate for the first time, that furin cleavage 
of L2 causes quaternary changes in the HPV16 capsid. This will help in the development of 
novel strategies to target HPV16 entry and infection, with the long-term aim to decrease the 
incidence of HPV associated cancers. Future work could be to apply a focussed refinement 
approach (60, 186) to both the furin uncleaved and furin cleaved HPV16 PsV reconstructions 
produced here, to possibly determine the effect of furin cleavage on the arrangement of L2 
density within the capsid. Additionally, molecular dynamics using a heparin molecule docked 
into the putative heparin-binding site would also add further insight into the effects of furin 
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Complete cell culture medium: Dulbecco’s Modified Eagle Medium (DMEM) (Sigma-Alrich) 
supplemented with 10% heat inactivated Foetal Calf Serum (FCS) (Biochrom), penicillin (100 
U/mL), streptomycin (100 U/mL) 
Light CsCl: 54 g CsCl, 200 mL 1xHSB buffer, filter sterilised 
Heavy CsCl: 77.6 g CsCl, 200 mL 1xHSB buffer, filter sterilised 
7.5% SDS-PAGE separating gels: 3.8 mL 40% Acrylamide, 5 mL Tris (1.5M, pH 8.8), 0.2 
mL 10% Sodium Dodecyl Sulphate (SDS), 11 mL dH2O, 20 µL TEMED, 100 µL 10% 
ammonium persulphate 
l3% SDS-PAGE stacking gel: 1.3mL 40% Acrylamide, 1.25mL Tris (1M; pH 6.8), 0.1mL 10% 
Sodium Dodecyl Sulphate, 7.4mL dH2O, 20µL TEMED, 50µL ammonium persulphate 
(10%)  
10x SDS-PAGE running buffer: 30g Solid Tris, 144g Solid Glycine, 10g SDS, made up to 1 
litre with dH2O 
1x SDS-PAGE running buffer: 10x running buffer was diluted 1:9 with dH2O to form 1X SDS-
PAGE buffer 
Pierce Silver Staining kit sensitizer solution: 25 µL sensitizer, 12.5 µL ultrapure dH2O  
Pierce Silver Staining kit working solution: 250 µL enhancer, 12.5mL Silver stain 
Pierce Silver Staining kit staining solution: 250 µL enhancer, 12.5mL developer 
2x HBS buffer: 50mM HEPES, 280 mM NaCl, 1.5 mM Na2PO4 (pH = 7.1), filter sterilised 
5x HSB buffer: 125 mM HEPES, 2.5 M NaCl, 0.1% Brij58, 5 mM MgCl2, 500 μM EDTA, 2.5% 
ethanol; filter sterilised 
 
